2022 Annual Report
[This Page Intentionally Left Blank]
Fellow Shareholders,
Today’s semiconductor industry is in transition from the high growth environment of 2020/2021 to the
rapid slowdown which began in Q4 of 2022. This pattern is familiar to industry veterans who have lived
with similar cycles for decades. Uncertainties are widespread, but one thing is clear, the best path forward
is to innovate through this period and exit the slowdown with new competitive advantage. This is also the
time when Atomera’s market prospects are most abundant.
Mears Silicon Technology (MST), our ground-breaking transistor enhancement material, was specifically
invented to help semiconductor designers achieve performance gains and cost reductions that are difficult
or impossible to achieve with other techniques. As industry players look for ways to create new
opportunities, our portfolio is ready to help them. Likewise, as the US looks to enable more domestic
innovation in semiconductors through the Chips and Science Act, MST is a proven tool to help achieve
those goals.
In 2022 Atomera made impressive progress in our core product development areas of analog and power
devices, RFSOI products, and 3D digital logic technologies and promoted those efforts with a number of
white papers, industry conferences and publications. We announced a new JDA and license partners and
established our reputation with the world’s leading-edge developers while simultaneously solidifying our
patent portfolio and development tools. These efforts are constructing a foundation for a sustainable, high
leverage, licensing business model of the future.
The present market environment is ripe for our customers to develop solutions conferring long term
competitive advantage, and Atomera’s technology is the easiest and most cost-effective way for them do
so. Thank you for your continued trust and support as we travel this path together,
Scott A. Bibaud
President and Chief Executive Officer
Atomera Incorporated
March 2023
750 University Avenue, Suite 280 | Los Gatos, CA 95032
| fx. 408-560-9556 | www.atomera.com
408-442-5248
[This Page Intentionally Left Blank]
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2022
or
☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-37850
ATOMERA INCORPORATED
(Exact name of registrant as specified in its charter)
Delaware
(State or Other jurisdiction of Incorporation or Organization)
30-0509586
(I.R.S. Employer Identification Number)
750 University Avenue, Suite 280
Los Gatos, California 95032
(Address, including zip code, of registrant’s principal executive offices)
(408) 442-5248
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common stock: Par value $0.001
Trading Symbol(s)
ATOM
Name of each exchange on which registered
Nasdaq Capital Market
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to
submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company
or an emerging growth company (as defined in Rule 12b-2 of the Exchange Act):
Large accelerated filer ☐
Non-accelerated filer ☒
Accelerated filer ☐
Smaller reporting company ☒
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal
control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. Yes ☐ No ☒
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒
State the aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to the price at which the
common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently
completed second fiscal quarter: $209,768,392. Shares of the registrant’s common stock held by each executive officer, director and holder of 10%
or more of the outstanding common stock (as determined based on public filings) have been excluded in that such persons may be deemed to be
affiliates. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.
As of February 8, 2023, there were 23,972,753 shares of the registrant’s common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days after the end of the fiscal year ended
December 31, 2022. Portions of such proxy statement are incorporated by reference into Part III of this Form 10-K.
ATOMERA INCORPORATED
TABLE OF CONTENTS
PART I
Item 1. Business ................................................................................................................................................................
Item 1A. Risk Factors ..........................................................................................................................................................
Item 1B. Unresolved Staff Comments.................................................................................................................................
Item 2.
Properties ..............................................................................................................................................................
Item 3. Legal Proceedings ................................................................................................................................................
Item 4. Mine Safety Disclosures .......................................................................................................................................
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities ..............................................................................................................................................................
Item 6. Reserved ...............................................................................................................................................................
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations ...............................
Item 7A. Quantitative and Qualitative Disclosures About Market Risk ..............................................................................
Item 8.
Financial Statements and Supplementary Data ....................................................................................................
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure ...............................
Item 9A. Controls and Procedures .......................................................................................................................................
Item 9B. Other Information .................................................................................................................................................
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections ..................................................................
PART III
Item 10. Directors, Executive Officers and Corporate Governance ...................................................................................
Item 11. Executive Compensation ......................................................................................................................................
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters .............
Item 13. Certain Relationships and Related Transactions and Director Independence ......................................................
Item 14. Principal Accountant Fees and Services ...............................................................................................................
PART IV
Page
1
9
15
15
15
15
16
16
17
21
22
40
40
40
40
41
41
41
41
41
Item 15. Exhibits, Financial Statement Schedules ..............................................................................................................
Item 16. Form 10-K Summary............................................................................................................................................
42
43
Signatures .............................................................................................................................................................
44
i
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are
intended to be covered by the “safe harbor” created by those sections. The words “believe,” “may,” “will,” “potentially,” “estimate,”
“continue,” “anticipate,” “intend,” “could,” “would,” “should,” “ongoing,” “project,” “plan,” “expect” and similar expressions that
convey uncertainty of future events or outcomes are intended to identify forward-looking statements. These forward-looking
statements include, but are not limited to, statements concerning the following:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
our future financial and operating results;
our intentions, expectations and beliefs regarding anticipated growth, technology adoption, market penetration and
trends in our business;
the timing and success of our plan of commercialization;
our ability to operate our license and royalty-based business model;
the effects of market conditions on our stock price and operating results;
our ability to maintain our competitive technological advantages against competitors in our industry;
our ability to have our technology solutions gain market acceptance;
our ability to maintain, protect and enhance our intellectual property;
the effects of competition in our market and our ability to compete effectively;
costs associated with initiating and defending intellectual property infringement and other claims;
our expectations concerning our relationships with customers, potential customers, partners and other third parties;
the attraction and retention of qualified employees and key personnel;
future acquisitions of or investments in complementary companies or technologies; and
our ability to comply with evolving legal standards and regulations, particularly concerning requirements for being a
public company.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described
in “Risk Factors” and elsewhere in this Annual Report and our subsequently filed Quarterly Reports on Form 10-Q. Moreover, we
operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for us to
predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light
of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report may
not occur and actual results could differ materially and adversely from those anticipated or implied in our forward-looking statements.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity,
performance or events and circumstances described in the forward-looking statements will be achieved or occur. Moreover, neither
we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake
no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report to conform these
statements to actual results or to changes in our expectations, except as required by law.
You should read this Annual Report and the documents that we reference in this Annual Report and have filed with the
Securities and Exchange Commission as exhibits with the understanding that our actual future results, levels of activity, performance
and events and circumstances may be materially different from what we expect.
ii
Item 1. Business
Company Overview
PART I
We are engaged in the business of developing, commercializing and licensing proprietary processes and technologies for
the $550+ billion semiconductor industry. Our lead technology, named Mears Silicon Technology™, or MST®, is a thin film of
reengineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied
as a transistor channel enhancement to CMOS-type transistors, the most widely used transistor type in the semiconductor industry.
MST is our proprietary and patent-protected performance enhancement technology that we believe addresses a number of key
engineering challenges facing the semiconductor industry. We believe that by incorporating MST, transistors can be made smaller,
with increased speed, reliability and power efficiency. In addition, since MST is an additive and low-cost technology, we believe it
can be deployed on an industrial scale, with machines commonly used in semiconductor manufacturing. We believe that MST can
be widely incorporated into the most common types of semiconductor products, including analog, logic, optical and memory
integrated circuits.
We do not intend to design or manufacture integrated circuits directly. Instead, we develop and license technologies and
processes that we believe offer the designers and manufacturers of integrated circuits a low-cost solution to the industry’s need for
greater performance and lower power consumption. Our customers and partners include:
• foundries, which manufacture integrated circuits on behalf of fabless manufacturers;
• integrated device manufacturers, or IDMs, which are the fully-integrated designers and manufacturers of integrated circuits;
• fabless semiconductor manufacturers, which are designers of integrated circuits that outsource the manufacturing of their
chips to foundries;
• original equipment manufacturers, or OEMs, that manufacture the epitaxial, or epi, machines used to deposit semiconductor
layers, such as the MST film, onto silicon wafers; and
• electronic design automation companies, which make tools used throughout the industry to simulate performance of
semiconductor products using different materials, design structures and process technologies.
We currently generate revenue through licensing arrangements whereby our customers initially pay us a fee for an
integration license that provides them the right to use MST technology (with MST film deposited for the customer by Atomera) in
the manufacture of silicon wafers for internal testing and sampling. Our goal is for each integration license to be the first of a three-
stage licensing process with the customer, with the first integration stage to be followed by one or more agreements granting them
manufacturing and distribution licenses. Our manufacturing license grants our customer rights to manufacture MST-enabled products
for internal use only and the grant typically occurs when we deliver our MST film recipe to the customer. A distribution license
grants the customer the rights to manufacture MST-enabled products for sale to their customers. Agreements granting manufacturing
and distribution licenses provide for substantially larger upfront license fee payments than the integration licenses, and distribution
agreements will require licensees to make royalty payments to us based on the number and sales price of MST-enabled products
they sell to their customers. We also generate revenue through engineering services provided to customers during their evaluation
of MST technology. Starting in late 2020, we have been providing our MSTcad software which enables customers to simulate the
effects of MST on their products using Synopsys, Inc.’s technology computer-aided design, or TCAD, software.
Starting in 2019, we began to develop deeper relationships with several potential large scale customers who were evaluating
MST across multiple manufacturing processes and product lines. Accordingly, we have begun engaging with certain customers under
an engagement format called a joint development agreement, or JDA, to certain customers. Our JDAs are customized to each
customer’s goals and they include development, technology transfer, manufacturing and licensing components.
In January 2021, we entered into a JDA with a leading semiconductor provider for integration of our MST technology into
their manufacturing process. Under this JDA, we granted our customer a paid manufacturing license pursuant to which the customer
installed the recipe for our MST film into a tool in their fab and was authorized to fabricate semiconductor wafers incorporating
MST for internal use. This JDA also includes development milestones that we achieved in February 2022, resulting in additional
revenue to us. Although this JDA does not confer commercial distribution rights, we believe that successful achievement of the JDA
milestones is a significant step toward commercialization, as it should facilitate progress toward integrating MST into one or more
of our customer’s multiple production lines and thus provide opportunities for additional license revenues and potential royalty
streams. In April 2022, we entered into a JDA with a major semiconductor foundry which contains technical targets which, if
achieved, should result in a paid licenses and engineering services revenue. Although this JDA does not confer commercial
distribution rights, we believe that achievement of the JDA’s technical objectives would be a significant step toward
commercialization.
1
In September and October 2018, respectively, we entered into separate integration license agreements with Asahi Kasei
Microdevices, or AKM, and STMicroelectronics, or ST, both of which are leading IDMs. In October 2019, we entered into an
integration license agreement with a leading fabless RF semiconductor provider. In February 2022, we entered into an integration
license agreement with a semiconductor foundry. Under the integration license agreements, these customers have paid us for the
right to evaluate MST technology, which is integrated onto their semiconductor wafers. We deposit MST onto the customers’ wafers
and the customer has the right under the license agreement to complete the manufacturing process, which enables them to evaluate
our technology and to provide limited samples to their customers. These agreements do not grant our customers the right to deposit
MST at their site or to sell products incorporating MST.
To date, initial application of our MST technology has been for power devices, RFSOI devices and advanced CMOS
integrated circuits. CMOS integrated circuits are the most widely used type of integrated circuits in the semiconductor industry. As
applied to CMOS-type transistors, MST functions as a transistor channel enhancement. We believe MST has the potential to
overcome the key challenges found in the implementation of next generation nano-scale semiconductor devices incorporating CMOS
type transistors, namely enhancing drive current, reducing gate leakage and reducing variability. In addition, we believe that MST
has the potential to deliver these benefits through a single technology that requires relatively minor modifications to the industry-
standard CMOS manufacturing flow. Consequently, we believe that by incorporating MST, designers can make transistors with
increased speed, reliability and energy efficiency, without significantly altering the current fabrication process or cost of production.
We were organized as a Delaware limited liability company under the name Nanovis LLC on November 26, 2001. On
March 13, 2007, we converted to a Delaware corporation under the name Mears Technologies, Inc. On January 12, 2016, we changed
our name to Atomera Incorporated. Shares of our common stock are listed on the NASDAQ Capital Market under the symbol
“ATOM”.
Industry Overview
Semiconductors, Generally
Recent years have seen a remarkable proliferation of consumer and commercial products, especially in wireless, automotive
and high-speed devices. Cloud computing and artificial intelligence technologies have provided people with new ways to create,
store and share information. At the same time, the increasing use of electronics in cars, buildings, appliances and other consumer
products is creating a broad landscape of “smart” devices such as wearable technologies and The Internet of Things. These trends in
both enterprise and consumer applications are driving increasing demand for integrated circuits and systems with greater
functionality and performance, reduced size, and much less power consumption as key requirements. The COVID-19 pandemic
accelerated trends toward remote work, cloud computing and mobile devices. These trends coincided with the rollout of 5G cellular
networks and 5G-enabled devices, growing popularity of augmented and virtual reality technologies and the growth in popularity of
cryptocurrencies, all of which require high levels of processing power.
These developments depend, in large part, on integrated circuits, or microchips, which are sets of electronic circuits on a
single chip of semiconductor material, normally silicon. It is common for a single semiconductor chip to combine many components
(processor, communications, memory, custom logic, input/output) resulting in highly complex chip designs. Transistors are the
building blocks of integrated circuits and the most complex semiconductor chips today contain more than a billion transistors, each
of which may have features that are much less than 1/1,000th the diameter of a human hair.
The most widely used transistors in semiconductor chips today are based on CMOS technology. Among its many attributes,
CMOS allows for a higher density of transistors on a chip and lower power usage than non-CMOS technologies.
The Pursuit of Increased Semiconductor Performance
For years, the semiconductor industry was able to almost double the number of transistors it could pack into a single
microchip about every two years, a rate of improvement commonly known as “Moore’s Law.” The semiconductor industry uses the
term “node” to describe the minimum line width or geometry on a semiconductor chip, expressed in nanometers, or nm, for today’s
technologies. Historically, smaller nodes enables more densely packed designs that produced less costly products on a per-transistor
basis. Frequently, smaller nodes also correspond to an improvement in chip performance, making them the mile markers of Moore’s
Law, with each node marking a new generation of chip-manufacturing technology.
Until recently, the industry succeeded at maintaining the rate of improvement predicted by Moore’s Law by scaling the key
transistor parameters, such as shrinking feature sizes and reducing operating voltages, thereby allowing more transistors to be packed
onto a single microchip. This trend was facilitated in large part by the development of CMOS technologies. However, a discontinuity
in the rate of improvement delivered by scaling appeared when transistor technology reached feature sizes below 100 nanometers.
The industry responded with advanced materials to supplement the ongoing geometry shrinks. Some of those materials advances
included strained silicon, Silicon-on-Insulator and High-K/Metal Gate. Semiconductor makers also attempted to obtain performance
2
improvements through more exotic design architectures which frequently required material innovations to support their
manufacturability and reliability.
The designers and manufacturers of integrated circuits and systems — our targeted customers — are facing intense pressure
to deliver innovative products while constantly reducing their time-to-market and prices. In other words, innovation in chip and
system design today often hinges on “better, sooner and cheaper.” We believe that the semiconductor industry has accepted that
moving forward in the nano-era will require adoption of new innovations that extend the scaling formula, including those based on
the use of new engineered materials, a market opportunity our MST technology seeks to address. Because shrinking geometries at
the smaller nodes incurs higher capital and manufacturing costs, only a limited number of companies can afford to continue investing
in those nodes. We believe these constraints will cause semiconductor designers and manufacturers to turn to engineered materials,
like MST, to solve this problem.
Vertical Disaggregation of the Industry
In trying to keep research and development costs manageable, while attempting to satisfy the demand for increasingly
complex semiconductors, certain designers and manufacturers of integrated circuits have transitioned to a more open innovation
model in which competing companies and third-party providers actively collaborate to address performance issues through various
alliances, joint ventures, and licensing of externally developed technology.
Historically, most semiconductor companies were vertically integrated. They designed, fabricated, packaged and tested
their semiconductors using internally developed software design tools and manufacturing processes and equipment. As the cost and
skills required for designing and manufacturing complex semiconductors have increased, the semiconductor industry has become
disaggregated, with companies concentrating on one or more individual stages of the semiconductor development and production
process. This disaggregation has fueled the growth of fabless semiconductor companies, design tool vendors, semiconductor
equipment manufacturers, third-party semiconductor manufacturers (or foundries), semiconductor assembly, package and test
companies, and intellectual property companies that develop and license technology to others.
While specialization has enabled greater development and manufacturing efficiency, it has also created an opportunity for
licensing companies, such as Atomera, that develop and license technology to meet fundamental, industry-wide challenges. These
intellectual property companies have been able to gain broad adoption of their technology throughout the industry by working with
companies within the semiconductor supply chain to evaluate and integrate their technology. Manufacturers and designers of
semiconductors increasingly find it more cost-effective to license technologies from IP-based companies than to develop processes
internally that are not their core competence. We believe this collaboration and integration of externally-developed IP benefits
semiconductor companies by enabling them to bring new technology to market faster and more cost-effectively.
Applications of Mears Silicon Technology
The initial applications of MST are for power devices, RFSOI devices and advanced CMOS integrated circuits. We offer
MST-SP, which is a type of MST-enabled power device that offers what we believe to be industry-leading on-resistance (also referred
to as Rsp) and reduced footprint (enabling smaller devices). We believe that the MST-SP devices will have immediate application
in power management integrated circuits (or PMICs) which are pervasive in hand-held, battery-powered devices and elsewhere. We
also believe that insertion of MST can provide higher current and improved control of dopants, leading to improved device scaling.
We believe MST has the potential to overcome the key challenges found in the implementation of next generation nano-
scale semiconductor devices incorporating CMOS-type transistors, namely enhancing drive current, reducing gate leakage and
reducing variability. In addition, we believe that MST has the potential to deliver these benefits through a single technology that
requires relatively minor modifications to the industry standard CMOS manufacturing flow. Consequently, we believe that by
incorporating MST, designers can make transistors with increased speed, reliability and energy efficiency, without significantly
altering the current fabrication process or cost of production.
3
As illustrated by the accompanying diagram, MST is a “silicon-on-silicon” solution that provides multiple potential benefits
through a relatively simple modification to the standard CMOS manufacturing flow. MST improvements are delivered through our
proprietary and patent-protected approach that is based on the quantum mechanics of modern deep sub-micron devices. The MST
film allows carriers (electrons and holes) to flow more freely in the plane of the transistor, thereby enhancing drive current, while
reducing carrier flow or “leakage” in the transverse direction. Our MST film can also create more controlled doping profiles, which
allow dopants to be held in the desired locations, thereby enabling optimized device designs, lower variability and improved
production yield.
We believe the enhancements enabled by MST, as demonstrated in simulations and on our own and our customers’ test
chips, are approximately equivalent to the enhancements enabled by one-half to a full node of improvement and, therefore, can
extend the productive life of capital equipment and wafer fabrication facilities. The extent of MST-enabled enhancement depends
on the device technology and application. We believe that MST compares favorably to other alternatives for enhancing performance
of CMOS-type transistors as follows:
•
Strained Silicon and Silicon-on-Insulator, or SOI: Unlike strained silicon or SOI, we believe that MST delivers multiple
benefits in a single film in a cost-effective manner, including enhanced transistor drive current, reduced leakage, and
reduced variability. Also, strained silicon tends to lose much of its effectiveness below 45nm, constraining its
scalability, while our results to date indicate that the MST thin-film approach is scalable to the leading-edge nodes used
for three-dimensional transistor devices using FinFET and “gate-all-around” structures. Based on our own research and
development and third-party evaluations, we believe that MST can deliver improved cost-benefit performance, in most
cases in an additive manner, compared to already successful strain technologies, such as dual stress liners and SiGe.
Work with our foundry partners and fabless licensee shows potential for additive improvements on specialized SOI
wafers used to manufacture radio frequency, or RF, devices, which are also referred to as RFSOI wafers.
• High-K/Metal Gate, or HKMG: Unlike HKMG, MST is silicon-based. As a “silicon-on-silicon” solution, MST does
not require new materials or equipment, which in our opinion makes it much easier and less costly to adopt than HKMG
for devices not requiring ultrathin gate dielectrics. For devices with HKMG, lab tests and simulations indicate that
MST benefits transistor performance and variability in a similar manner to the benefits observed in non-HKMG
devices. Testing conducted with our university research partners indicates that MST has the potential to provide
additive performance benefits in devices using HKMG.
Because of its physical characteristics in the channel region of the transistor, we believe MST has the further benefit of
being complementary and additive to the performance-enhancing technologies noted above, making MST broadly applicable across
multiple devices and process flows to meet a wide variety of customer design objectives. Given the costs of moving to more advanced
technologies, we believe one of the most compelling aspects of MST is its cost/benefit profile. We believe that MST will provide a
lower cost of production due to our technology’s potential to reduce die size while leveraging existing manufacturing tools, thereby
providing chip makers with increased performance at all process nodes with significantly fewer disruptions to manufacturing
processes and less incremental cost than other advanced technologies.
4
We believe MST can improve transistor performance in a variety of device types including microprocessors; logic products;
analog, RF, and mixed-signal devices; as well as DRAM, SRAM, and other memory integrated circuits. We have therefore developed
different MST product options that can be applied to the critical industry segments and technology nodes. As of the date of this
Annual Report, we have done technology simulation work with universities and leading industry players at nodes from 180nm to
5nm. We have also simulated devices with leading industry research facilities and built and electrically verified test chips using MST
in customer manufacturing facilities which have produced results that demonstrate many of the benefits described above.
Development Partnerships
TSI Semiconductors. Since 2016 we have worked under a Master R&D Services Agreement with TSI Technology
Development & Commercialization Services LLC (or TSI). Under this agreement, TSI provides us with engineering services in their
semiconductor manufacturing facility in California. By running tests in TSI's facility, which we utilize to run tests on a contract
basis, we are able to build and test devices that incorporate MST much more quickly than when we test in our potential customers'
facilities. We believe this arrangement enables faster product development, test, and integration, and should accelerate our time to
market.
Synopsys. Since 2017 we have worked in collaboration with Synopsys, Inc., a provider of the most broadly used TCAD
simulation software in the semiconductor industry. As a result of our collaboration, Synopsys’ software now supports modeling of
MST, which enables semiconductor manufacturers and designers to model the interaction of MST with other process steps. In
December 2020, we announced availability of our MSTcadTM software which runs on Synopsys’ Sentaurus TCAD software and
enables semiconductor engineers to simulate the benefits of integrating MST in a variety of devices. We continually refine our
MSTcad software by calibrating our models against measured silicon results and we regularly release updates to that software. We
believe these capabilities are helping us focus integration efforts for potential customers more quickly on those areas most likely to
deliver benefits, thus shortening test cycles and, we believe, accelerating the time to a license decision. In the last three years,
semiconductor fabs have generally been running at high capacity to keep up with industry supply shortages which has made it
challenging for us to run wafers through our customers’ fabrication lines. MSTcad has been increasingly used by existing and
potential customers to identify applications where MST can have the greatest benefit, without requiring access to customer fabs.
Epi Tool Lease. In August 2021 we completed the acceptance process of an Applied Materials Centura epitaxial deposition
reactor which handles both 200mm and 300mm wafers. We utilize this tool under a five-year lease and perform deposition on both
customer and internal R&D wafers. The terms of our tool lease include the lessor’s maintenance and support as well as access to a
clean-room with advanced cleaning and inspection tools.
MST Commercialization
We do not intend to design or manufacture integrated circuits directly. Instead, we develop and license technologies and
processes that offer the designers and manufacturers of integrated circuits increased performance at a lower cost than currently-
available alternatives. Our customers and partners include foundries, integrated device manufacturers, or IDMs, fabless
semiconductor manufacturers, OEMs that manufacture epitaxial deposition, or EPI, machines, and electronic design automation
software companies, such as Synopsys.
Our business model is to enter into licensing arrangements whereby foundries and IDMs pay us a license fee for their use
of MST technology in the manufacture of silicon wafers as well as a royalty for each silicon wafer (in the case of foundries) or device
(in the case of IDMs) that they sell that incorporates MST. In the case of fabless semiconductor licensees, our strategy is to charge
a royalty for each device they sell that incorporates our MST technology. The primary beneficiaries of our commercialization
activities are the IDMs and fabless semiconductor manufacturers, as they produce and distribute the integrated circuit devices which
are enhanced when they incorporate MST technology. The foundries and OEMs also play an important role in our commercialization
strategy because these parties traditionally seek to provide new and improved technologies to their customers – the fabless
semiconductor manufacturers in the case of the foundries, and the IDMs and foundries in the case of the OEMs.
In the semiconductor industry, new technologies are vetted thoroughly and carefully by early adopters who are trying to
achieve differentiation over competitors. After the early adopters prove the technology in production, it then tends to be broadly and
relatively quickly adopted by “followers” who need to overcome their competitive disadvantage. Due to the cost and complexity of
semiconductor manufacturing processes and the desire to maintain a stable and repeatable process flow, new technologies tend to be
adopted broadly by the industry and, wherever possible, exploited for several generations until they are fully optimized and adoption
costs are fully absorbed.
Although each customer or potential customer follows an evaluation and adoption model that is particular to its business
model and product focus, our engagements generally consist of the following phases:
1. Engineering Planning: In this phase we engage in a technical exchange of information under a non-disclosure
agreement to understand the customer’s manufacturing process and to determine how best to integrate the deposition
of MST film onto the customer’s semiconductor wafers.
5
2. Set-up for MST Integration: We agree upon the technical evaluation details, including the expected rounds of evaluation
testing, the parameters to be tested and allocation of costs. Customers provide us with wafers for our internal processing
and physical characterization. Some customers work together with us to develop a TCAD model showing possible
results of MST integration with their particular manufacturing process.
3. MST Integration. Typically, this phase includes several rounds of tests that involve building test devices on a
semiconductor wafer using our MST technology within the customer’s manufacturing process flow. In this phase, we
perform the MST deposition on customer wafers, so wafers must be shipped back and forth between the customer and
Atomera. We believe that this phase will continue to be the longest in our customer engagement process because
integrating into a customer’s flow frequently requires us to conduct subsequent tests based on the result of earlier test
runs. This phase also requires investment of time and resources by customers. In order to progress beyond this phase,
we must demonstrate benefits at a commercially significant level. It is difficult for both customers and for Atomera to
estimate the amount of time a customer will be in the integration phase.
4. Process Installation. Prior to enabling a customer to install and use MST technology on epitaxial deposition machines
in their own fab, we require execution of a manufacturing license which grants rights limited to manufacturing MST-
enabled products for internal R&D and qualification, but does not give the customer the right to distribute or sell
products that use MST. The JDA that we announced in January 2021 granted a manufacturing license to our customer
enabling the customer to install the MST film recipe in an epi tool in their fab for its internal use, at which point this
customer entered Phase Four.
5. Technology qualification. After installation of MST in the fab, the customer will conduct additional testing to ensure
manufacturing reliability under accelerated test conditions that simulate volume production. Upon successfully
completing the qualification phase, products can be built and shipped using this manufacturing process. We have not
had any customer move into Phase Five as of the date of this Annual Report.
6. Production. We expect that our license agreements will provide that upon commencement of sales of wafers or devices
built using MST, our customer will pay us a royalty that will be a percentage of the selling price of the wafer or device,
depending on the type of customer.
While the above steps describe a model customer engagement, we have engaged with some customers in ways that do not
follow this precise order. JDAs are an example of an engagement format that may combine engineering service, development,
manufacturing, process optimization and other joint activities that do not follow the order described above. In addition, we may from
time to time enter into evaluation license agreements with certain customers under which they may install MST in their fabs to run
internal tests only and not for commercial use or distribution. Other potential customers may run tests on wafers containing MST
prior to further engagement with us to integrate MST into their manufacturing process.
We believe that our success is dependent upon the adoption of our MST technology through to commercial production by
at least one IDM, foundry, or fabless semiconductor manufacturer. As of the date of this Annual Report, MST was in the integration
phase (Phase Three as described above) on 14 different engagements and one engagement in Phase Four (process installation).
Subject to process and subsequent product qualifications that demonstrate, in commercial scale production, the enhancements we
believe our MST technology offers, including increased speed, reliability and energy efficiency, we expect that one or more of these
companies will obtain licenses from us to take our MST technology to commercial production.
We are also working with OEMs on process development and equipment optimization to ensure that MST can be reliably
and predictably deposited using their manufacturing tools. We have successfully deposited MST using tools made by each of the
leading epitaxial deposition equipment suppliers and we believe that if we are successful in our commercialization efforts, these tool
OEMs will promote the incorporation of our MST technology as an option to their standard offering. By doing so, we believe they
will simultaneously stimulate additional sales of their capital equipment and encourage more customers to adopt MST.
Through our collaboration with Synopsys, we enable potential customers of MST to more quickly assess the potential
benefits of MST to their semiconductor devices. By creating TCAD software models, we can work with manufacturers to assess
which of their product types would most benefit from MST. We believe this modeling capability has shortened the time required for
us to engage with new potential customers and should ultimately lead to a faster decision process by the customer regarding licensing
MST.
We market our MST technology directly to the semiconductor industry through our significant industry contacts and
relationships. We also sponsor academic research and participate in industry conferences and associations. In certain foreign
jurisdictions, we engage sales representatives to assist us in establishing relationships with local customers.
6
Customers
In January 2021, we entered into a JDA with a leading semiconductor provider for integration of our MST technology into
their manufacturing process. Under this JDA we granted our customer a paid manufacturing license pursuant to which the customer
installed the recipe for our MST film into a tool in their fab and was authorized to fabricate semiconductor wafers incorporating
MST for internal use. This JDA also includes development milestones that we achieved in February 2022, resulting in additional
revenue to us. Although this JDA does not confer commercial distribution rights, we believe that successful achievement of the JDA
milestones is a significant step toward commercialization as it should facilitate progress toward integrating MST into one or more
of our customer’s multiple production lines and thus provide opportunities for additional license revenues and potential royalty
streams. In April 2022, we entered into a JDA with a major semiconductor foundry.
In September and October 2018, respectively, we entered into separate integration license agreements with AKM and ST,
both of which are leading IDMs. In October 2019 we entered into an integration license agreement with a leading fabless RF
semiconductor provider. In February 2022 we entered into an integration license agreement with a semiconductor foundry. Under
the integration license agreements, these customers have each agreed to pay us for the right to evaluate MST technology which is
integrated onto their semiconductor wafers. We deposit MST onto the customers’ wafers and the customer has the right under the
license agreement to complete the manufacturing process which enables them to evaluate our technology. These agreements do not
grant the customer the right to deposit MST at their site or to sell products incorporating MST and all of our licensees are in our
Phase Three (MST Integration).
We intend that each integration license agreement will be the first of a three-stage licensing process with each of AKM,
ST, our RF licensee and our foundry licensee, to be followed by manufacturing and distribution license agreements with each of
them. Those manufacturing and distribution license agreements, if executed, will allow each licensee to manufacture – or in the case
of our RF licensee, to have its foundry partner manufacture – MST-enabled products and to sell them to their customers. We expect
that the manufacturing and distribution agreements will provide for substantially larger upfront license fee payments than the
integration license fees and will require the respective licensees to make royalty payments to us based on the number and sales price
of MST-enabled products they sell to their customers. However, our ability to enter into royalty-based manufacturing and distribution
agreements with our licensees under our integration license agreements will depend, in large part, on the performance of devices
they build using MST and the successful integration of our MST technology on a high-volume production scale. There can be no
assurance that our MST technology will deliver the performance, power, cost reduction or other requirements our customers seek
for their products or that the integration of our technology with our customers’ manufacturing process will be successful in high
volume. In addition, even if our MST technology meets our customers’ technical objectives one or more of our licensees may decide,
for reasons unrelated to the price or performance of our MST technology, not to enter into manufacturing and distribution license
agreements.
Competition
Our lead product, MST, is a proprietary and patent-protected performance enhancement technology that we believe
addresses a number of key engineering challenges facing the semiconductor industry. Historically, development of a new material
technology for the semiconductor industry has taken 10-20 years from conceptualization to volume production. Atomera’s MST
technology has followed a similar trajectory, from early patents, publications and presentations to the industry to early evaluations
and installation at customers.
We compete with IDMs, OEMs, foundries, fabless manufacturers of semiconductors and semiconductor IP licensing
companies for the development and commercialization of technologies that improve the performance of semiconductors.
Historically, when a new fabrication process proves to be a low-cost improvement to the standard fabrication process, and is additive,
rather than in place of other performance technologies, it has been successfully adopted industry-wide. Good examples of such
advances have been chemical mechanical polishing (or CMP), strained silicon and High-K/Metal-Gate. We believe that MST has
the potential to be one of these low-cost additive technologies, in which case MST would not be subject to significant direct
competition from other technologies. We are not aware of another technology being offered in the market which provides the same
technical benefits as MST. Nevertheless, in some cases the engineering teams in our customers, who are developing their own
process improvements, may view MST as competition to their internally-developed solutions.
Research and Development
The principal focus of our research and development efforts is on enabling existing and prospective customers to integrate
MST into their manufacturing processes and enable them to commercialize MST-enabled semiconductor products. We also dedicate
research and development resources to evolving and expanding our technology to address new process technologies in the
semiconductor industry roadmap. Our research and development is conducted internally, but we work closely with third parties in
the semiconductor industry to evaluate and qualify our technology for incorporation into semiconductor products and fabrication
equipment. During the years ended December 31, 2022 and 2021, we incurred research and development expenses of approximately
$10.0 million and $8.8 million, respectively.
7
We believe that our success depends in part on our ability to achieve the following in a cost-effective and timely manner:
•
•
•
•
enable customers to integrate MST into their products;
develop new technologies that meet the changing needs of the semiconductor industry;
improve our existing technologies to enable growth into new application areas; and
expand our intellectual property portfolio.
Intellectual Property Rights
We regard the protection of our technologies and intellectual property rights as an important element of our business
operations and crucial to our success. We rely primarily on a combination of patent laws, trade secret laws, confidentiality
procedures, and contractual provisions to protect our proprietary technology. We require our employees, consultants, and advisors
to enter into confidentiality agreements. These agreements provide that all confidential information developed or made known to the
individual during the course of the individual’s relationship with us is to be kept confidential and not disclosed to third parties except
under specific circumstances. In the case of our employees and consultants, the agreements provide that all of the technology that is
conceived by the individual during the course of employment is our exclusive property. The development of our technology and
many of our processes are dependent upon the knowledge, experience, and skills of key scientific and technical personnel.
As of December 31, 2022, we have been granted 126 patents in the U.S. and 107 abroad. Our core patents relating to MST
cover materials, physical structures and manufacturing processes. Our core patents relating to MST were filed beginning on August
22, 2003 and have grant dates beginning on December 14, 2004. Our MST patent portfolio begins to expire commencing August 22,
2023. Our patent portfolio has grown significantly over the last five years and during 2022 we were issued 20 new patents worldwide,
an annual increase of 9%. We believe our core patents adequately block competitors from using our MST technology without our
approval and our patent activity over the past five years has focused on extending the scope of our portfolio through a variety of
means, including but not limited to patenting new structures, materials and methods uniquely enabled by MST technology. However,
there can be no assurance that one or more of our patents would survive a legal challenge to their scope, validity, or enforceability,
or provide significant protection for us. The failure of our patents, or the failure of trade secret laws, to adequately protect our
technology, might make it easier for our competitors to offer similar products or technologies or for our potential customers to build
products with methods and materials similar to MST without paying us a license fee. In addition, patents may not issue from any of
our current or future applications.
We also hold registered trademarks in the United States for the marks “Atomera” and “MST” and in China for the mark
“Mears”. We have applied with the U.S. Patent and Trademark Office for the registration of the mark “MSTcad” in the United States.
Employees and Human Capital Management
As of the date of this Annual Report, we employ 21 people on a full-time basis.
Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and
integrating our existing and new employees. The principal purposes of our equity incentive plans are to attract, retain and reward
personnel through the granting of stock-based compensation awards that align their compensation with our business objectives and
with creation of shareholder value.
Available Information
Our website is located at www.atomera.com. The information on or accessible through our website is not part of this Annual
Report on Form 10-K. Copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-
K and amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of
charge, on our investor relations website as soon as reasonably practicable after we file such material electronically with or furnish
it to the Securities and Exchange Commission, or the SEC. A copy of this Annual Report on Form 10-K is also located at the SEC’s
Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Information on the operation of the Public Reference Room
can be obtained by calling the SEC at 1-800-SEC-0330. The SEC also maintains an internet site that contains reports and other
information regarding our filings at www.sec.gov.
8
Item 1A. Risk Factors
We are subject to various risks that may harm our business, prospects, financial condition and results of operation or prevent us
from achieving our goals. If any of these risks occur, our business, financial condition or results of operation may be materially
adversely affected. In such case, the trading price of our common stock could decline and investors could lose all or part of their
investment.
Risks Related to Our Business
We only recently commenced limited revenue producing operations, so it is difficult for potential investors to evaluate
our business. To date, our operations have consisted of technology research and development, testing, and joint development work
with customers, potential customers and strategic partners. Our business model is to derive our revenue primarily from license fees
and royalties, but to date we have only recognized minimal engineering services and licensing revenues. Our limited operating
history makes it difficult to evaluate the commercial value of our technology or our prospective operations. As an early-stage
company, we are subject to all the risks inherent in the initial organization, financing, expenditures, complications and delays in a
new business, including, without limitation:
•
•
•
•
•
•
•
•
•
the timing and success of our plan of commercialization and the fact that we have not entered into a royalty-based
manufacturing or distribution license with a potential customer;
our ability to replicate on a large commercial scale the benefits of our MST technology that we have demonstrated in
preliminary testing;
our ability to execute joint development agreements with potential customers;
our ability to structure, negotiate and enforce license agreements that will allow us to operate profitably;
our ability to advance the licensing arrangements with our initial integration licensees, Asahi Kasei Microdevices,
STMicroelectronics, our foundry licensee and our RF licensee, to royalty-based manufacturing and distribution
licenses;
our success in capitalizing on the achievement of the technical milestones in our first JDA in order to enter into one or
more distribution and royalty agreements with business units of that JDA customer as well as our success in meeting
technical milestones in the JDA with our second JDA customer;
our ability to successfully operate, the epitaxial deposition reactor for processing 300mm wafers, together with
supporting equipment, that we recently began using for internal research and development and to support customer
activities;
our ability to protect our intellectual property rights; and
our ability to raise additional capital as and when needed.
Investors should evaluate an investment in us in light of the uncertainties encountered by developing companies in a
competitive environment. There can be no assurance that our efforts will be successful or that we will ultimately be able to attain
profitability.
We have a history of significant operating losses and anticipate continued operating losses for at least the near term.
For the years ended December 31, 2022 and 2021, we have incurred net losses of approximately $17.4 million and $15.7 million,
respectively, and our operations have used approximately $12.5 million and $12.4 million of cash, respectively. As of December 31,
2022, we had an accumulated deficit of approximately $183.3 million. We will continue to experience negative cash flows from
operations until at least such time as we are able to secure manufacturing and distribution license agreements with one or more
foundries, IDMs or fabless semiconductor manufacturers. While management will endeavor to generate positive cash flows from
the commercialization of our MST technology, there can be no assurance that we will be successful doing so. If we are unable to
generate positive cash flow within a reasonable period of time, we may be unable to further pursue our business plan or continue
operations.
While we have entered into four integration license agreements and two joint development agreements, there can be no
assurance that any of these relationships will advance to further licensing stages or to royalty-based distribution license
agreements. In September and October 2018, respectively, we entered into separate license agreements with AKM and ST, both of
which are leading IDMs. In October 2019, we entered into a license agreement with a leading RF semiconductor supplier. In
December 2021, we entered into a JDA with a leading semiconductor manufacturer. In February 2022, we entered into an integration
9
license agreement with a semiconductor foundry. In April 2022 we entered into a JDA with a major semiconductor foundry. Our
integration licensees have paid us licensing fees for the right to build products that integrate MST technology onto their
semiconductor wafers, but the agreements do not grant the licensees the right to sell products incorporating MST. Such rights require
our integration licensees to enter into additional license agreements that, if executed, would allow each licensee or their foundry to
manufacture MST-enabled products and to sell them to their customers. We expect that the manufacturing and distribution
agreements will provide for substantially larger upfront license fee payments than integration license fees and that the agreements
will require the respective licensees to make royalty payments to us based the number and sales price of MST-enabled products they
sell to their customers. However, our ability to enter into royalty-based manufacturing and distribution agreements with our current
integration licensees or with new customers will depend, in large part, on the performance of devices they build using MST and the
successful integration of our MST technology on a high-volume production scale. Our first JDA customer paid us for a manufacturing
license in the first quarter of 2021 when we delivered our MST recipe to them. In February 2022, we successfully achieved all the
development milestones in the JDA resulting in additional revenue. Nevertheless, neither of our JDAs commits the customers to take
MST to production. There can be no assurance that our MST technology will deliver the performance, power or other requirements
our customers seek for their products or that the integration of our technology with our customers’ manufacturing process will be
successful in high volume. In addition, even if our MST technology is successfully integrated into the licensees’ products, any or all
of our licensees may decide, for reasons unrelated to the price or performance of our MST technology, not to enter the subsequent
license agreements required to take MST to commercial production.
AKM, one of our licensees, suffered a total loss of one of its fabs due to a fire, impacting their production capability and
delaying their work with us. On October 20, 2020, a fire broke out in AKM’s factory in Nobeoka, Japan which lasted three days,
causing substantial damage to the building and equipment. AKM subsequently decided not to resume manufacturing at that site.
Although Atomera’s work under our integration license agreement with AKM did not involve wafers in commercial production in
this fab, the fire substantially disrupted AKM’s business and interrupted their integration and testing of MST. We expect that
cooperation on integrating MST into AKM’s products will continue, but the fire has cast doubt on the timing for moving toward a
manufacturing license or commercial distribution as AKM has moved production previously carried out in the Nobeoka fab to an
external foundry.
We expect that our product qualification and licensing cycle will be lengthy and costly, and our marketing, engineering
and sales efforts may be unsuccessful. We have incurred significant engineering, marketing and sales expenses during customer
engagements without entering into license agreements, generating a license fee or establishing a royalty stream from the customer
and we expect that such investments ahead of license revenue will continue to be necessary in the future. The introduction of any
new process technology into semiconductor manufacturing is a lengthy process and we cannot forecast with any degree of assurance
the length of time it takes to establish a new licensing relationship. However, based on our engagements with potential customers to
date, we believe the time from initial engagement until our customers incorporate our technologies in their semiconductor products,
can take 18 to 36 months or longer. Our integration license agreements with our current licensees do not commit them to
manufacturing or distribution licenses and we expect those licensees to perform additional tests on evaluation wafers under their
respective integration licenses before deciding whether to enter the next stages of licensing MST. As such, we will incur additional
expenses in our engagements with our licensees before we receive license fees, if any, for manufacturing and distribution and before
any subsequent royalty stream begins. Although we have successfully completed the objectives of our first JDA and granted that
customer a manufacturing license, the agreement does not commit our customer to a distribution license. While we believe our JDAs
and our integration license agreements should accelerate licensing decisions by other customers, the evaluation process for new
technologies in the semiconductor industry is inherently long and complex and there can be no assurance that we will successfully
convert other customer prospects into paying customers or that any of these customers will generate sufficient revenue to cover our
expenses.
Qualification of our MST technology requires access to our potential customers’ manufacturing tools and facilities, as
well as to leased tools and facilities, which may not be available on a timely basis or at all. The qualification of a new process
technology like MST entails the integration of our MST film into the complex manufacturing processes employed by our potential
customers. In order to validate the benefits of MST, our customer engagement process involves fabrication of wafers that incorporate
MST deposited by us using our epitaxial deposition tools and then completing the manufacturing of the wafers in our customers’
facilities using their tools. The semiconductor industry in 2022 exceeded $550 billion in sales, and over the past three years the
industry has been characterized by product shortages as strong demand has outstripped supply, resulting in tight capacity among our
potential customers. Although these supply/demand imbalances and tight capacity conditions have eased in recent months, we have
experienced delays in completing the processing of evaluation wafers by our customers as those customers prioritize utilization of
their equipment for production use. If our customers do not dedicate their equipment and facilities to testing our products in a timely
fashion, we may experience delays that will increase our expenses and delay our customers’ decisions on entering into a commercial
license with us. Additionally, we conduct our ongoing research and development and portions of our customer evaluation activities
using a leased epitaxial (epi) deposition tool that we believe will accelerate internal development work and customer engagements.
However, epi tools require ongoing, complex maintenance and they have been and will continue to be subject to both planned and
unplanned downtime. Any interruption in our epi tool availability may negatively impact the progress of customer work as well as
our internal research and development and accordingly could delay or prevent customers from entering into commercial licenses.
10
The long-term success of our business is dependent on a royalty-based business model, which is inherently risky. The
long-term success of our business is dependent on future royalties paid to us by licensee-customers, whose business requires them
to market products to their end customers. Royalty payments under our licenses are generally expected to be based on a percentage
(i) in the case of foundries, the selling price of wafers made using MST and (ii) in the case of IDMs and fabless vendors, the selling
price of MST-enabled semiconductor die sold. We will depend upon our ability to structure, negotiate and enforce agreements for
the determination and payment of royalties, as well as upon our licensees’ compliance with their agreements. We face risks inherent
in a royalty-based business model, many of which are outside of our control, such as the following:
•
•
•
•
•
•
•
•
the rate of adoption and incorporation of our technology by semiconductor designers and manufacturers and the
manufacturers of semiconductor fabrication equipment;
customers’ willingness to agree to an ongoing royalty model, which may impact their wafer or chip costs and
margins;
our licensee customers’ ability to successfully market MST-enabled products to their end customers;
the length of the design cycle and the ability to successfully integrate our MST technology into integrated circuits;
the demand for products incorporating semiconductors that use our licensed technology;
the cyclicality of supply and demand for products using our licensed technology;
the impact of economic downturns; and
the timing of receipt of royalty reports and the applicable revenue recognition criteria, which may result in fluctuation
in our results of operations.
We may need additional financing to execute our business plan and fund operations, which additional financing may
not be available on reasonable terms or at all. As of December 31, 2022, we had total assets of approximately $26.7 million, cash
and cash-equivalents of approximately $21.2 million and working capital of approximately $18.7 million. We believe that we have
sufficient capital to fund our current business plans and obligations over, at least, the 12 months following the date of this Annual
Report. However, even after installation of MST in a customer’s fab under a manufacturing license, the full production qualification
of a new technology like MST can take more than an additional year, and we have limited ability to influence our customers’ testing
and qualification processes. Accordingly, we may require additional capital prior to obtaining a royalty-based license or prior to such
a license generating sufficient royalty income to cover our ongoing operating expenses. In the event we require additional capital
over and above the amount of our presently available working capital, we will endeavor to seek additional funds through various
financing sources, including the sale of our equity and debt securities, licensing fees for our technology and joint ventures with
industry partners. In addition, we will consider alternatives to our current business plan that may enable to us to achieve material
revenue with a smaller amount of capital. However, there can be no guarantees that such funds will be available on commercially
reasonable terms, if at all. If such financing is not available on satisfactory terms, we may be unable to further pursue our business
plan and we may be unable to continue operations.
Our revenues may be concentrated in a few customers and if we lose any of these customers, or these customers do not
If we are able to secure the adoption of our MST by one or more
pay us, our revenues could be materially adversely affected.
foundries, IDMs or fabless semiconductor manufacturers, we expect that for at least the first few years substantially all of our revenue
will be generated from license fees and engineering services before customers commence royalty-bearing shipments. Due to the
concentration and ongoing consolidation within the semiconductor industry, we may also find that over the longer term our royalty-
based revenues are dependent on a relatively few customers. If we lose any of these customers, or these customers do not pay us,
our revenues could be materially adversely affected.
If we are unable to manage future expansion effectively, our business, operations and financial condition may suffer
significantly, resulting in decreased productivity. If our MST proves to be commercially valuable, it is likely that we will experience
a rapid growth phase that could place a significant strain on our managerial, administrative, technical, operational and financial
resources. Our organization, procedures and management may not be adequate to fully support the expansion of our operations or
the efficient execution of our business strategy. If we are unable to manage future expansion effectively, our business, operations
and financial condition may suffer significantly, resulting in decreased productivity.
It may be difficult for us to verify royalty amounts owed to us under our licensing agreements, and this may cause us to
lose revenues. We will endeavor to provide that the terms of our license agreements require our licensees to document their use of
our technology and report related data to us on a regular basis. We will endeavor to provide that the terms of our license agreements
give us the right to audit books and records of our licensees to verify this information, however audits can be expensive, time
consuming, and may not be cost justified based on our understanding of our licensees’ businesses. We will endeavor to audit certain
11
licensees to review the accuracy of the information contained in their royalty reports in an effort to decrease the likelihood that we
will not receive the royalty revenues to which we are entitled under the terms of our license agreements, but we cannot give
assurances that such audits will be effective to that end.
Our business operations could suffer in the event of information technology systems’ failures or security breaches.
While we believe that we have implemented adequate security measures within our internal information technology and networking
systems, our information technology systems may be subject to security breaches, damages from computer viruses, natural disasters,
terrorism, and telecommunication failures. Any system failure or security breach could cause interruptions in our operations,
including but not limited to our technology computer-aided design, or TCAD, modeling using Synopsys software, in addition to the
possibility of losing proprietary information and trade secrets. To the extent that any disruption or security breach results in
inappropriate disclosure of our confidential information, our competitive position may be adversely affected, and we may incur
liability or additional costs to remedy the damages caused by these disruptions or security breaches.
If integrated circuits incorporating our technologies are used in defective products, we may be subject to product liability
or other claims. If our MST technology is used in defective or malfunctioning products, we could be sued for damages, especially
if the defect or malfunction causes physical harm to people. While we will endeavor to carry product liability insurance, contractually
limit our liability and obtain indemnities from our customers, there can be no assurance that we will be able to obtain insurance at
satisfactory rates or in adequate amounts or that any insurance and customer indemnities will be adequate to defend against or satisfy
any claims made against us. The costs associated with legal proceedings are typically high, relatively unpredictable and not
completely within our control. Even if we consider any such claim to be without merit, significant contingencies may exist, similar
to those summarized in the above risk factor concerning intellectual property litigation, which could lead us to settle the claim rather
than incur the cost of defense and the possibility of an adverse judgment. Product liability claims in the future, regardless of their
ultimate outcome, could have a material adverse effect on our business, financial condition and reputation, and on our ability to
attract and retain licensees and customers.
Risks Related to Intellectual Property
If we fail to protect and enforce our intellectual property rights and our confidential information, our business will
suffer. We rely primarily on a combination of nondisclosure agreements and other contractual provisions and patent, trade secret
and copyright laws to protect our technology and intellectual property. If we fail to protect our technology and intellectual property,
our licensees and others may seek to use our technology and intellectual property without the payment of license fees and royalties,
which could weaken our competitive position, reduce our operating results and increase the likelihood of costly litigation. The growth
of our business depends in large part on our ability to secure intellectual property rights in a timely manner, our ability to convince
third parties of the applicability of our intellectual property rights to their products, and our ability to enforce our intellectual property
rights. In certain instances, we attempt to obtain patent protection for portions of our technology, and our license agreements typically
include both issued patents and pending patent applications as well as our proprietary know-how. If we fail to obtain patents in a
timely manner or if the patents issued to us do not cover all of the inventions disclosed in our patent applications, others could use
portions of our technology and intellectual property without the payment of license fees and royalties.
We also rely on trade secret laws rather than patent laws to protect other portions of our proprietary technology. However,
trade secrets can be difficult to protect. The misappropriation of our trade secrets or other proprietary information could seriously
harm our business. We protect our proprietary technology and processes, in part, through confidentiality agreements with our
employees, consultants, suppliers and customers. We cannot be certain that these contracts have not been and will not be breached,
that we will be able to timely detect unauthorized use or transfer of our technology and intellectual property, that we will have
adequate remedies for any breach, or that our trade secrets will not otherwise become known or be independently discovered by
competitors. If we fail to use these mechanisms to protect our technology and intellectual property, or if a court fails to enforce our
intellectual property rights, our business will suffer. We cannot be certain that these protection mechanisms can be successfully
asserted in the future or will not be invalidated or challenged.
Further, the laws and enforcement regimes of certain countries do not protect our technology and intellectual property to
the same extent as do the laws and enforcement regimes of the U.S. In certain jurisdictions, we may be unable to protect our
technology and intellectual property adequately against unauthorized use, which could adversely affect our business.
A court invalidation or limitation of our key patents could significantly harm our business. Our patent portfolio contains
some patents that are particularly significant to our MST technology. If any of these key patents are invalidated, or if a court limits
the scope of the claims in any of these key patents, the likelihood that companies will take new licenses and that any current licensees
will continue to agree to pay under their existing licenses could be significantly reduced. The resulting loss in license fees and
royalties could significantly harm our business. Moreover, our stock price may fluctuate based on developments in the course of
ongoing litigation.
We may become involved in material legal proceedings in the future to enforce or protect our intellectual property rights,
which could harm our business. From time to time, we may identify products that we believe infringe our patents. In that event, we
expect to initially seek to license the manufacturer of the infringing products, however if the manufacturer is unwilling to enter into
12
a license agreement, we may have to initiate litigation to enforce our patent rights against those products. Litigation stemming from
such disputes could harm our ability to gain new customers, who may postpone licensing decisions pending the outcome of the
litigation or who may, as a result of such litigation, choose not to adopt our technologies. Such litigation may also harm our
relationships with existing licensees, who may, because of such litigation, cease making royalty or other payments to us or challenge
the validity and enforceability of our patents or the scope of our license agreements.
In addition, the costs associated with legal proceedings are typically high, relatively unpredictable and not completely within
our control. These costs may be materially higher than expected, which could adversely impair our working capital, affect our
operating results and lead to volatility in the price of our common stock. Whether or not determined in our favor or ultimately settled,
litigation would divert our managerial, technical, legal and financial resources from our business operations. Furthermore, an adverse
decision in any of these legal actions could result in a loss of our proprietary rights, subject us to significant liabilities, require us to
seek licenses from others, limit the value of our licensed technology or otherwise negatively impact our stock price or our business
and financial position, results of operations and cash flows.
Even if we prevail in our legal actions, significant contingencies may exist to their settlement and final resolution, including
the scope of the liability of each party, our ability to enforce judgments against the parties, the ability and willingness of the parties
to make any payments owed or agreed upon and the dismissal of the legal action by the relevant court, none of which are completely
within our control. Parties that may be obligated to pay us royalties could be insolvent or decide to alter their business activities or
corporate structure, which could affect our ability to collect royalties from such parties.
Our technologies may infringe on the intellectual property rights of others, which could lead to costly disputes or
disruptions. The semiconductor industry is characterized by frequent allegations of intellectual property infringement. Any
allegation of infringement could be time consuming and expensive to defend or resolve, result in substantial diversion of management
resources, cause suspension of operations or force us to enter into royalty, license, or other agreements rather than dispute the merits
of such allegation. Furthermore, third parties making such claims may be able to obtain injunctive or other equitable relief that could
block our ability to further develop or commercialize some or all of our technologies, and the ability of our customers to develop or
commercialize their products incorporating our technologies, in the U.S. and abroad. If patent holders or other holders of intellectual
property initiate legal proceedings, we may be forced into protracted and costly litigation. We may not be successful in defending
such litigation and may not be able to procure any required royalty or license agreements on acceptable terms or at all.
Risks Related to Owning Our Common Stock
The market price of our shares may be subject to fluctuation and volatility. You could lose all or part of your investment.
The market price of our common stock is subject to wide fluctuations in response to various factors, some of which are beyond our
control. Between January 1, 2022 and February 8, 2023, the reported high and low sales prices of our common stock have ranged
from $5.75 to $21.28. The market price of our shares on the NASDAQ Capital Market may fluctuate as a result of a number of
factors, some of which are beyond our control, including, but not limited to:
•
actual or anticipated variations in our results of operations and financial condition;
• market acceptance of our MST technology;
•
•
•
•
•
•
•
•
•
success or failure of our research and development projects;
announcements of technological innovations by us;
failure by us to achieve a publicly announced milestone;
failure by us to meet expectations of investors, some of which may not be within our control or related to our public
announcements;
delays between our expenditures to develop and market new or enhanced technological innovations and the generation
of licensing revenue from those innovations;
developments concerning intellectual property rights, including our involvement in litigation brought by or against
us;
changes in the amounts that we spend to develop, acquire or license new technologies or businesses;
our sale or proposed sale, or the sale by our significant stockholders, of our shares or other securities in the future;
changes in our key personnel;
13
•
•
•
changes in earnings estimates or recommendations by securities analysts, if we continue to be covered by analysts;
the trading volume of our shares; and
general economic and financial market conditions and other factors, including factors unrelated to our operating
performance.
These factors and any corresponding price fluctuations may materially and adversely affect the market price of our shares
and result in substantial losses being incurred by our investors. In the past, following periods of market volatility, public company
stockholders have often instituted securities class action litigation. If we were involved in securities litigation, it could impose a
substantial cost upon us and divert the resources and attention of our management from our business.
We have not paid dividends in the past and have no immediate plans to pay dividends. We plan to reinvest all of our
earnings, to the extent we have earnings, to cover operating costs and otherwise become and remain competitive. We do not plan to
pay any cash dividends with respect to our securities in the foreseeable future. We cannot assure you that we would, at any time,
generate sufficient surplus cash that would be available for distribution to the holders of our common stock as a dividend. Therefore,
you should not expect to receive cash dividends on our common stock.
We expect to continue to incur significant increased costs as a result of being a public company that reports to the
Securities and Exchange Commission and our management will be required to devote substantial time to meet compliance
obligations. As a public company reporting to the Securities and Exchange Commission, we incur significant legal, accounting and
other expenses that we did not incur as a private company. We are subject to reporting requirements of the Exchange Act and the
Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the Securities and Exchange Commission that impose
significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and
financial controls and changes in corporate governance practices. In addition, on July 21, 2010, the Dodd-Frank Wall Street Reform
and Protection Act was enacted. There are significant corporate governance and executive compensation-related provisions in the
Dodd-Frank Act that increased our legal and financial compliance costs, make some activities more difficult, time-consuming or
costly and may also place undue strain on our personnel, systems and resources. Our management and other personnel devote a
substantial amount of time to these compliance initiatives.
Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable. Provisions of our
certificate of incorporation and bylaws and applicable provisions of Delaware law may delay or discourage transactions involving
an actual or potential change in control or change in our management, including transactions in which stockholders might otherwise
receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. The
provisions in our certificate of incorporation and bylaws:
•
•
•
•
•
limit who may call stockholder meetings;
do not permit stockholders to act by written consent;
allow us to issue blank check preferred stock without stockholder approval;
do not provide for cumulative voting rights; and
provide that all vacancies may be filled by the affirmative vote of a majority of directors then in office, even if less
than a quorum.
In addition, Section 203 of the Delaware General Corporation Law may limit our ability to engage in any business
combination with a person who beneficially owns 15% or more of our outstanding voting stock unless certain conditions are satisfied.
This restriction lasts for a period of three years following the share acquisition. These provisions may have the effect of entrenching
our management team and may deprive you of the opportunity to sell your shares to potential acquirers at a premium over prevailing
prices. This potential inability to obtain a control premium could reduce the price of our common stock.
Our bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain
litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial
forum for disputes with the Company. Our bylaws provide that, unless we consent in writing to the selection of an alternative forum,
the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding
brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other
employees to us or our stockholders, (iii) any action asserting a claim against us or any our directors, officers or other employees
arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws, or (iv) any
action asserting a claim against us or any our directors, officers or other employees governed by the internal affairs doctrine. This
14
forum selection provision in our bylaws may limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us
or any our directors, officers or other employees.
Our board of directors may issue blank check preferred stock, which may affect the voting rights of our holders and
could deter or delay an attempt to obtain control of us. Our board of directors is authorized, without stockholder approval, to issue
preferred stock in series and to fix and state the voting rights and powers, designation, preferences and relative, participating, optional
or other special rights of the shares of each such series and the qualifications, limitations and restrictions thereof. Preferred stock
may rank prior to our common stock with respect to dividends rights, liquidation preferences, or both, and may have full or limited
voting rights. If issued, such preferred stock would increase the number of outstanding shares of our capital stock, adversely affect
the voting power of holders of our common stock and could have the effect of deterring or delaying an attempt to obtain control of
us.
Item 1B. Unresolved Staff Comments
None.
Item 2.
Properties
Our executive offices are presently located in a 4,101 square foot facility in Los Gatos, California pursuant to a five-year
lease, expiring on January 31, 2026. As part of the amended lease entered into in August 2020, our current lease payment is $17,185.
We lease shared office space in Cambridge Massachusetts from which we conduct certain research activities. The
Cambridge facilities are occupied pursuant to a month-to-month lease at a rate of $2,942 per month which has been effective since
January 1, 2020.
Beginning in March 2021, we began leasing 474 square feet of office space in Tempe, Arizona. This lease has a two-year
term, with an option to extend for an additional three years. The renewal option was exercised in January 2023. Our current monthly
lease payment is $1,239 and will increase to $1,277 in March 2023.
Item 3.
Legal Proceedings
To our knowledge, as of the date of this Annual Report, there are no pending legal proceedings to which we or our properties
are subject.
Item 4.
Mine Safety Disclosures
Inapplicable.
15
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities Market Information
PART II
Our common stock trades on the NASDAQ Capital Market under the symbol “ATOM”.
Holders of Record
As of February 1, 2023, there were 151 holders of record of our common stock.
Dividend Policy
We have never declared or paid cash dividends on our common stock. We presently intend to retain earnings, if any, to
finance the operation and expansion of our business.
Equity Compensation Plan Information
Our 2007 Equity Incentive Plan, or 2007 Plan, expired in March 2017, however all options and warrants outstanding at the
time of the expiration remained outstanding and exercisable by their term. As of December 31, 2022, options to purchase [•] shares
of common stock were outstanding.
In May 2017, we established our 2017 Stock Incentive Plan, or 2017 Plan. The 2017 Plan provides for the grant of non-
qualified stock options and incentive stock options to purchase shares of our common stock and for the grant of restricted and
unrestricted share grants. We have reserved a total of 3,750,000 shares of common stock for issuance under the 2017 Plan. All
employees, officers, directors, consultants, advisors and other persons who provide services to us or any of our subsidiaries are
eligible to receive incentive awards under the 2017 Plan. As of December 31, 2022, awards of 3,072,791 shares of common stock
had been granted under the 2017 Plan, net of forfeited restricted stock and option awards and a total of 677,209 shares of common
stock are reserved for issuance.
The following table sets forth certain information as of December 31, 2022 about our stock plans under which our equity
securities are authorized for issuance (in thousands, except exercise price).
Number of
Securities to be
Issued Upon
Exercise of
Outstanding
Options
(a)
Weighted-
Average
Exercise Price of
Outstanding
Options
Number of
Securities
Remaining
Available for
Future Issuance
Under Equity
Compensation
Plans (Excluding
Securities
Reflected In
Column (a))
3,009 $
–
3,009 $
7.07
–
7.07
677
–
677
Plan Category
Equity compensation plans approved by security holders
Equity compensation plans not approved by security holders
Total
Item 6.
Reserved
16
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of the financial condition and results of operations of Atomera Incorporated should
be read in conjunction with our financial statements and the accompanying notes that appear elsewhere in this Annual Report.
Statements in this Annual Report on Form 10-K include forward-looking statements based upon current expectations that involve
risks and uncertainties, such as our plans, objectives, expectations and intentions. We use words such as “anticipate,” “estimate,”
“plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar
expressions to identify forward-looking statements. Although forward-looking statements in this Annual Report reflect the good faith
judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-
looking statements are inherently subject to risks, uncertainties, and changes in condition, significance, value and effect, including
those risk factors set forth in this Annual Report. Such risks, uncertainties and changes in condition, significance, value and effect
could cause our actual results to differ materially from those expressed herein and in ways not readily foreseeable. Readers are
urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report and
are based on information currently and reasonably known to us. We undertake no obligation to revise or update any forward-looking
statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to
carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the
risks and factors that may affect our business, financial condition, results of operations and prospects.
Overview
We are engaged in the business of developing, commercializing and licensing proprietary processes and technologies for
the $550+ billion semiconductor industry. Our lead technology, named Mears Silicon Technology™, or MST®, is a thin film of
reengineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied
as a transistor channel enhancement to CMOS-type transistors, the most widely used transistor type in the semiconductor industry.
MST is our proprietary and patent-protected performance enhancement technology that we believe addresses a number of key
engineering challenges facing the semiconductor industry. We believe that by incorporating MST, transistors can be made smaller,
with increased speed, reliability and power efficiency. In addition, since MST is an additive and low-cost technology, we believe it
can be deployed on an industrial scale, with machines commonly used in semiconductor manufacturing. We believe that MST can
be widely incorporated into the most common types of semiconductor products, including analog, logic, optical and memory
integrated circuits.
We do not intend to design or manufacture integrated circuits directly. Instead, we develop and license technologies and
processes that we believe offer the designers and manufacturers of integrated circuits a low-cost solution to the industry’s need for
greater performance and lower power consumption. Our customers and partners include:
•
•
•
•
•
foundries, which manufacture integrated circuits on behalf of fabless manufacturers;
integrated device manufacturers, or IDMs, which are the fully-integrated designers and manufacturers of integrated
circuits;
fabless semiconductor manufacturers, which are designers of integrated circuits that outsource the manufacturing of
their chips to foundries;
original equipment manufacturers, or OEMs, that manufacture the epitaxial, or epi, machines used to deposit
semiconductor layers, such as the MST film, onto silicon wafers; and
electronic design automation companies, which make tools used throughout the industry to simulate performance of
semiconductor products using different materials, design structures and process technologies.
Our commercialization strategy is to generate revenue through licensing arrangements whereby foundries, IDMs and fabless
semiconductor manufacturers pay us a license fee for their right to use MST technology in the manufacture of silicon wafers as well
as a royalty for each silicon wafer or device that incorporates our MST technology. We also license our MSTcadTM software to our
customers for use in simulating the effects of using MST technology on their wafers and/or devices. To date, we have generated
revenue from (i) licensing agreements with two IDMs, one fabless manufacturer and one foundry, (ii) a joint development agreement,
or JDA, with a leading semiconductor provider, (iii) engineering services provided to foundries, IDMs and fabless companies and
(iv) licensing MSTcad.
We were organized as a Delaware limited liability company under the name Nanovis LLC on November 26, 2001. On
March 13, 2007, we converted to a Delaware corporation under the name Mears Technologies, Inc. On January 12, 2016, we changed
our name to Atomera Incorporated.
17
Between September 2020 and January 2021,we conducted an at-the-market offering of our common shares through Craig-
Hallum Capital Group LLC, as agent, pursuant to which we sold 2,221,575 shares at an average price per share of approximately
$11.25, resulting in approximately $24.2 million of net proceeds to us after deducting commissions and other offering expenses.
On May 31, 2022, we entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc and Craig-Hallum
Capital Group LLC, as agents, under which we may offer and sell, from time to time at our sole discretion, shares of our common
stock having aggregate offering proceeds of up to $50.0 million in an “at-the-market” or ATM offering, to or through the agents.
During the year ended December 31, 2022, approximately 527,000 shares were sold at an average price per share of approximately
$11.68, resulting in approximately $5.8 million of net proceeds to us after deducting commissions and other offering expenses.
Results of Operations for the Years Ended December 31, 2022 and 2021
Revenues. To date, we have only generated limited revenue from customer engagements for integration engineering
services, integration license agreements, a manufacturing license granted under a JDA, a success fee for achievement of milestones
under that JDA and licensing our MSTcad software. In the future, we expect to collect increased fees from license agreements and
JDAs as well as royalties from customer sales of products that incorporate our MST technology, subject to our ability to enter into
manufacturing and distribution license agreements with our current and future licensees. Our integration services consist of
depositing our MST film on semiconductor wafers, delivering such wafers to customers to finalize building devices, and performing
tests for customers evaluating MST. The integration license agreements we have entered into to date grant the licensees the right to
build products that integrate our MST technology deposited by us onto their semiconductor wafers, but the agreements do not grant
the licensees the rights to manufacture on their site or to sell products incorporating MST. Our first JDA included the grant of a
manufacturing license to our customer and we were paid for such license upon delivery of our IP transfer package which enabled
our customer to install MST in a tool in their facility and to use it to manufacture wafers for internal use. This JDA also contained
targeted technical specifications that, if met, would result in payment of a success fee to us. Those technical objectives were met and
we have collected the success fee.
For revenue recognition purposes, we have determined that the grant of rights in integration licenses is not distinct from the
delivery of integration services, and therefore revenue from both integration licenses and integration services is recognized as the
services are provided to the customer. In general, this is proportionate to the delivery of MST processed wafers to the customer, but
if the agreements do not specify a time and quantity of wafer delivery, we will record revenue over the period of time of which we
anticipate delivering an estimated quantity of wafers. We have also determined that the grant of our manufacturing license under the
JDA confers a right to use our technology and accordingly revenue was recognized at the point in time when we delivered our IP
transfer package. The success fee under our JDA was treated as engineering services revenue and recognized upon our customer’s
confirmation that the JDA’s technical objectives had been met. Our licensing of MSTcad grants customers the right to use MSTcad
software to simulate the effects of incorporating MST technology into their semiconductor manufacturing process. Such MSTcad
licenses are granted on a monthly basis and revenue is recognized over time.
Revenue for the years ended December 31, 2022 and 2021 was approximately $382,000 and $400,000, respectively. Our
revenue for 2022 consisted of a success fee pursuant to our JDA, a license fee paid under an integration license agreement and
MSTcad license revenue. Our revenue for 2021 consisted of a manufacturing license fee pursuant to our JDA.
Cost of Revenue. Cost of revenue consists of costs of materials, as well as direct compensation and expenses incurred to
provide integration engineering services. Cost of revenue was approximately $81,000 and $0 for the years ended December 31, 2022
and 2021, respectively. We anticipate that our cost of revenue will vary substantially depending on the mix of license and engineering
services revenues we receive and the nature of products and/or services delivered in each customer engagement.
Operating Expenses. Operating expenses consist of research and development, general and administrative, and selling and
marketing expenses. For the years ended December 31, 2022 and 2021 our operating expenses totaled approximately $17.8 million
and $15.9 million, respectively.
Research and development expense. To date, our operations have focused on the research, development, patent
prosecution, and commercialization of our MST technology and related technologies such as MSTcad. Our research and development
costs primarily consist of payroll and benefit costs for our engineering staff and costs of outsourced fabrication (including epi tool
leases) and metrology of semiconductor wafers incorporating our MST technology.
For the years ended December 31, 2022 and 2021, we incurred approximately $10.0 million and $8.8 million, respectively,
of research and development expense, an increase of approximately $1.3 million, or 14%. The increase was primarily due to
approximately $850,000 of increased tool lease related expenses as the tool lease commenced in August 2021, and increase of
approximately $246,000 in stock-based compensation and an increase of approximately $180,000 in technical consulting expenses.
General and administrative expense. General and administrative expenses consist primarily of payroll and benefit costs
for administrative personnel, office-related costs and professional fees. General and administrative costs for the years ended
December 31, 2022 and 2021 were approximately $6.4 million and $6.2 million, respectively, representing an increase of
18
approximately $277,000, or 4%. The increase in costs was primarily due to an increase of approximately $103,000 in patent fees
and legal fees associated with our patents, an increase of approximately $95,000 in insurance costs and increase of approximately
$86,000 in payroll related expenses.
Selling and marketing expense. Selling and marketing expenses consist primarily of salary and benefits for our sales and
marketing personnel and business development consulting services. Selling and marketing expenses for the years ended December
31, 2022 and 2021 were approximately $1.3 million and $986,000, respectively, representing an increase of approximately $362,000,
or 37%. The increase in costs is primarily related to increased spending in employee-related costs of approximately $104,000, an
increase in outsourced marketing expenses of approximately $83,000 and an increase in stock-based compensation of approximately
$77,000.
Interest income. Interest income for the years ended December 31, 2022 and 2021 was approximately $340,000 and $9,000,
respectively. Interest income for each period related to interest earned on our cash and cash equivalents and the increase was primarily
due to progressively higher interest rates during these periods.
Interest expense. Interest expense for the years ended December 31, 2022 and 2021 was approximately $255,000 and
$128,000, respectively. Interest expense is related to the new tool financing lease entered into in August 2021.
Provision for income taxes. The provision for income tax for the year ended December 31, 2021 was $66,000 and related
to income taxes due to a foreign country arising from withholding taxes imposed on payments received for revenue. There was no
provision for income tax recorded for the year ended December 31, 2022.
Liquidity and Capital Resources
As of December 31, 2022, we had cash and cash equivalents of approximately $21.2 million and working capital of
approximately $18.7 million. For the year ended December 31, 2022, we had a net loss of approximately $17.4 million and used
approximately $12.5 million of cash and cash equivalents in operations. Since inception, we have incurred recurring operating losses.
During the year ended December 31, 2022, we sold approximately 527,000 shares pursuant to our ATM at an average price
per share of approximately $11.68, resulting in approximately $5.8 million of net proceeds to us after deducting commissions and
other offering expenses
We believe that our available working capital is sufficient to fund our presently forecasted working capital requirements
for, at least, the next 12 months following the date of the filing of this report. However, our future capital requirements and the
adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our MST
technology, competing technological and market developments, and the need to enter into collaborations with other companies or
acquire technologies to enhance or complement our current offerings. If we are not able to generate sufficient revenue from license
fees and royalties in a time frame that satisfies our cash needs, we will need to raise more capital. In the event we require additional
capital, we will endeavor to acquire additional funds through various financing sources, including our ATM Facility, follow-on
equity offerings, debt financing and joint ventures with industry partners. In addition, we will consider alternatives to our current
business plan that may enable to us to achieve revenue-producing operations and meaningful commercial success with a smaller
amount of capital. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives
and take additional measures to reduce costs in order to conserve its cash.
Cash Flows from Operating, Investing and Financing Activities:
Net cash used in operating activities of approximately $12.5 million for year ended December 31, 2022 resulted primarily
from our net loss of approximately $17.4 million adjusted by approximately $3.4 million of stock-based compensation expense and
amortization of right-of-use assets of approximately $1.4 million
Net cash used in operating activities of approximately $12.4 million for year ended December 31, 2021 resulted primarily
from our net loss of approximately $15.7 million adjusted by approximately $3.0 million of stock-based compensation expense.
Net cash used by investing activities of approximately $39,000 and approximately $109,000 for the years ended December
31, 2022 and 2021, respectively, consisted of the purchase of computers, lab tools and leasehold improvements for the remodeled
Los Gatos office space and our new Tempe office space.
Net cash provided by financing activities of approximately $5.0 million for the year ended December 31, 2022. related
primarily to net proceeds from our at-the-market offering during the year ended December 31, 2022 offset in part by approximately
$984,000 in principal payments on our financing lease.
19
Net cash provided by financing activities of approximately $3.3 million for the year ended December 31, 2021 related to
the exercise of approximately 571,000 stock options and net proceeds from our at-the-market offering in January 2021. These
amounts were offset in part by approximately $470,000 in principal payments on our financing lease.
Critical Accounting Estimates
Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. The
preparation of financial statements in conformity with those accounting principles requires us to use judgement in making estimates
and assumptions based on the relevant information available at the end of each period. These estimates and assumptions have a
significant effect on reported amounts of assets, liabilities, sales and expenses as well as the disclosure of contingent assets and
liabilities because they result primarily from the need to make estimates and assumptions on matters that are inherently uncertain.
Actual results could differ from our estimates.
Revenue
We generate revenue from integration engineering services, which we deliver either pursuant to integration license
agreements or delivery of engineering services and from the grant of manufacturing licenses to customers to use its technology in
the manufacture of semiconductor wafers and/or devices for the customer’s internal use. Revenue is recognized based on the
following steps: (i) identification of the contract, or contracts, with a customer, (ii) identification of the performance obligations in
the contract, (iii) determination of the transaction price, (iv) allocation of the transaction price to the performance obligations of the
contract, and (v) recognition of revenue when, or as, we satisfy a performance obligation. Integration services generally consist of
depositing our proprietary technology onto the customer’s semiconductor wafers and delivering such wafers back to the customer.
Revenue from integration services is recognized as the performance obligations are satisfied, which is upon transfer of control of the
wafers to the customer (generally upon shipment). Revenue from manufacturing licenses is recognized as the performance
obligations are satisfied, which is upon delivery of the Company’s MST recipe to the customer.
For recognizing integration service revenue from integration license agreements, we assess (i) whether the license grant is
distinct from or combined with the transfer of goods or services and (ii) whether the license is a right to access intellectual property
or a right to use the intellectual property. For licenses that are not distinct, but combined with other goods or services, the revenue
is recognized at a point in time or over time as the obligations to perform the combined services and/or deliver the combined goods
are satisfied. Integration license agreements contain a technology grant as well as a performance obligation to deliver wafers with
our technology deposited on them. We have determined the grant of rights in these integration license agreements is not distinct
from the integration service. Accordingly, revenue from integration license agreements is recognized as the service is provided to
the customer. For manufacturing licenses, revenue is recognized at the point in time when we deliver our MST recipe as the license
to manufacture using MST technology is a right to use the Company’s technology and not a right to access the technology over time.
Leases
We account for leases in accordance with Financial Accounting Standards Board (“FASB”) issued Accounting Standards
Update (“ASU”) No 2016-02, Leases (Topic 842). We determine if a contract contains a lease in whole or in part at the inception of
the contract. Right-of-use (“ROU”) assets represent its right to use an underlying asset for the lease term while lease liabilities
represent its obligation to make lease payments arising from the lease. All leases greater than 12 months result in the recognition of
a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term.
Lease expenses for operating leases is recognized on a straight-line-basis over the lease term. Lease expenses for financing leases is
amortization of the he ROU assets over the life of the lease and interest expense is recognized on the liability.
Stock-based Compensation
We have stock-based compensation programs, which include restricted stock awards (“RSAs”) and stock options and an
employee stock purchase plan. We account for stock-based compensation expense, including the expense for grants of RSAs and
stock options that may be settled in shares of our common stock, based on the fair values of the equity instruments issued. The fair
value is determined on the measurement date, which is the date of grant. The fair value of our RSAs is measured at the market price
of our common stock on the measurement date amortized over the vesting period of the award. The fair value for our stock option
awards is determined at the grant date using the Black-Scholes Option Pricing Model and amortized over the vesting period of the
option.
20
Assumptions for the Black-Scholes valuation model used for employee stock awards include:
• Expected term – We derived the expected term for employee stock awards using limited historical information to develop
expectations about future exercise patterns and post vesting employment termination behavior.
• Expected volatility – Volatility is estimated using Atomera’s historical volatility for similar terms.
• Expected dividend rate – We have not declared or paid dividends to our stockholders and have no plans to pay dividends;
therefore, we have assumed an expected dividend yield of 0%.
• Risk-free interest rate – The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar
to the expected terms of the associated awards.
• The fair value of our common stock is measured at the market price on the measurement date.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Not applicable.
21
Item 8.
Financial Statements and Supplementary Data
Index to Financial Statements
Report of Independent Registered Public Accounting Firm ..............................................................................................
Balance Sheets at December 31, 2022 and 2021................................................................................................................
Statements of Operations for the years ended December 31, 2022 and 2021 ....................................................................
Statements of Stockholders’ Equity for the years ended December 31, 2022 and 2021 ....................................................
Statements of Cash Flows for the years ended December 31, 2022 and 2021 ...................................................................
Notes to the Financial Statements ......................................................................................................................................
Page
23
24
25
26
27
28
22
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors of
Atomera Incorporated
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Atomera Incorporated (the “Company”) as of December 31, 2022 and 2021,
the related consolidated statements of operations, stockholders’ equity and cash flows for each of the two years in the period ended
December 31, 2022, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the
results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with
accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the
Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with
the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we
express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe
that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required
to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements
and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.
/s/ Marcum LLP
Marcum LLP
We have served as the Company’s auditor since 2015.
Los Angeles, CA
February 15, 2023
23
Atomera Incorporated
Balance Sheets
(in thousands, except per share data)
ASSETS
Current Assets:
Cash and cash equivalents
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Long-term prepaid maintenance and supplies
Security deposit
Operating lease right-of-use-asset
Financing lease right-of-use-asset
December 31,
2022
2021
$
21,184 $
418
21,602
158
91
14
700
4,164
28,699
309
29,008
196
91
14
900
5,851
Total assets
$
26,729 $
36,060
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued expenses
Accrued payroll related expenses
Current operating lease liability
Current financing lease liability
Total current liabilities
Long-term operating lease liability
Long-term financing lease liability
Total liabilities
Commitments and contingencies (see Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 2,500 shares: none issued and
outstanding at December 31, 2022 and 2021
Common stock, $0.001 par value, authorized 47,500 shares; 23,973 shares issued and
outstanding at December 31, 2022 and 23,207 issued and outstanding as of
December 31, 2021
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity
$
397 $
173
967
245
1,126
2,908
521
2,986
6,415
–
–
338
203
601
216
1,395
2,753
768
4,158
7,679
–
–
24
203,585
(183,295 )
20,314
23
194,212
(165,854 )
28,381
Total liabilities and stockholders’ equity
$
26,729 $
36,060
The accompanying notes are an integral part of these financial statements.
24
Atomera Incorporated
Statements of Operations
(in thousands, except per share data)
Revenue:
Cost of revenue
Gross margin
Operating Expenses:
Research and development
General and administrative
Selling and marketing
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Total other income (expense), net
Net loss before income taxes
Provision for income taxes
Net loss
Net loss per common share, basic
Net loss per common share, diluted
Weighted average number of common shares outstanding, basic
Weighted average number of common shares outstanding, diluted
$
$
$
$
Years Ended December 31,
2022
2021
382 $
(81 )
301
10,038
6,441
1,348
17,827
400
–
400
8,779
6,164
986
15,929
(17,526 )
(15,529 )
340
(255 )
85
(17,441 )
–
(17,441 ) $
(0.75 ) $
(0.75 ) $
23,157
23,157
9
(128 )
(119 )
(15,648 )
66
(15,714 )
(0.70 )
(0.70 )
22,492
22,492
The accompanying notes are an integral part of these financial statements.
25
Atomera Incorporated
Statements of Stockholders’ Equity
(in thousands)
Balance January 1, 2021
Stock-based compensation
Warrant exercises
Stock option exercises
Forfeited restricted stock awards
At-the-market sale of stock, net of
commissions and expenses
Net loss
Balance December 31, 2021
Stock-based compensation
Stock option exercises
At-the-market sale of stock, net of
commissions and expenses
Net loss
Balance December 31, 2022
Common Stock
Shares
Amount
Additional
Paid-in
Capital
Accumulated
Deficit
Total
Stockholders’
Equity
22,375 $
89
223
571
(65 )
14
–
23,207 $
194
45
527
–
23,973 $
22 $
–
–
1
–
–
–
23 $
–
–
1
–
24 $
187,463 $
2,973
–
3,533
–
243
–
194,212 $
3,367
244
(150,140 ) $
–
–
–
–
–
(15,714 )
(165,854 ) $
–
–
5,762
–
203,585 $
–
(17,441 )
(183,295 ) $
37,345
2,973
–
3,534
–
243
(15,714 )
28,381
3,367
244
5,763
(17,441 )
20,314
The accompanying notes are an integral part of these financial statements.
26
Atomera Incorporated
Statements of Cash Flows
(in thousands)
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss
Adjustments to reconcile net loss to net cash used in operating activities:
Years Ended December 31,
2022
2021
$
(17,441 ) $
(15,714 )
Depreciation and amortization
Operating lease right of use asset amortization
Financing lease right of use asset amortization
Stock-based compensation
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Accounts payable
Accrued expenses
Accrued payroll expenses
Operating lease liability
Net cash used in operating activities
CASH FROM INVESTING ACTIVITIES
Acquisition of property and equipment
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from at-the-market sale of stock, net of commissions and expenses
Proceeds from exercise of stock options
Payments of principal for financing lease
Net cash provided by financing activities
Net increase/(decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental information:
Cash paid for interest
Cash paid for taxes
77
200
1,229
3,367
(108 )
59
(30 )
366
(218 )
(12,499 )
(39 )
(39 )
5,763
244
(984 )
5,023
67
186
532
2,973
(177 )
(104 )
(10 )
(104 )
(90 )
(12,441 )
(109 )
(109 )
243
3,534
(470 )
3,307
(7,515 )
(9,243 )
28,699
37,942
21,184 $
28,699
255 $
– $
128
66
$
$
$
The accompanying notes are an integral part of these financial statements.
27
1. NATURE OF OPERATIONS
Atomera Incorporated
Notes to the Financial Statements
Atomera Incorporated (“Atomera” or the “Company”) was incorporated in the state of Delaware in March 2007 under the
name MEARS Technologies, Inc. and is engaged in the development, commercialization and licensing of proprietary processes and
technologies for the semiconductor industry. On January 12, 2016, the Company changed its name to Atomera Incorporated.
Atomera is an early-stage company, having only recently begun limited revenue-generating activities, and is devoting
substantially all its efforts toward technology research and development and to commercially licensing its technology to designers
and manufacturers of integrated circuits.
2. LIQUIDITY AND MANAGEMENT PLANS
At December 31, 2022, the Company had cash and cash equivalents of approximately $21.2 million and working capital of
approximately $18.7 million. The Company has generated only limited revenues since inception and has incurred recurring operating
losses. Accordingly, it is subject to all the risks inherent in the initial organization, financing, expenditures, and scaling of a new
business that is not generating positive cashflow.
The Company has primarily financed operations through private placements of equity and debt securities, the Company’s
Initial Public Offering (the “IPO”) which was consummated on August 10, 2016, and subsequent public offerings of its common
stock. On May 31, 2022, Atomera entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc. and Craig-Hallum
Capital Group LLC, as agents, under which the Company may offer and sell, from time to time at its sole discretion, shares of its
$0.001 par value common stock, in “at the market” offerings to or through the agent as its sales agent, having aggregate offering
proceeds of up to $50.0 million (the “ATM Facility”).
Based on the funds it has available as of the date of the filing of this report, the Company believes that it has sufficient
capital to fund its current business plans and obligations over, at least, 12 months from the date that these financial statements have
been issued. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company’s ability to successfully commercialize its technology, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire technologies to enhance or complement its current offerings.
The Company’s operating plans for the next 12 months include increased research and development expenses. For capital needs
beyond the next 12 months, the Company currently expects to rely, in part, on its ATM, but the terms on which any future stock
sales will occur will depend on both market conditions and the Company’s business performance, so there can be no guarantee that
funds will be available on commercially reasonable terms.
3.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation
The financial statements are presented in accordance with accounting principles generally accepted in the United States of
America (“GAAP”) and reflect the financial position, results of operations and cash flows for all periods presented.
Fair Value of Financial Instruments
Authoritative guidance requires disclosure of the fair value of financial instruments. The Company’s financial instruments
consist of cash and cash equivalents, accounts receivable and accounts payable, the carrying amounts of which approximate their
estimated fair values primarily due to the short-term nature of the instruments or based on information obtained from market sources
and management estimates. The Company measures the fair value of certain of its financial assets and liabilities on a recurring basis.
A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and
liabilities carried at fair value which is not equivalent to cost will be classified and disclosed in one of the following three categories:
Level 1 — Quoted prices (unadjusted) in active markets for identical assets and liabilities.
Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for
similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or
can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of
the assets or liabilities.
28
Cash and cash equivalents
The Company maintains its operating accounts in a single reputable financial institution. The balances are insured by the
U.S. Federal Deposit Insurance Corporation (“FDIC”) up to specified limits. The Company’s cash and cash equivalents are
maintained in checking accounts and money market funds with maturities of less than three months when purchased, which are
readily convertible to known amounts of cash.
Concentration of Credit Risk and Major Customers
Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash,
cash equivalents and accounts receivable. Two customers each represented 79% and 20%,of revenue during the year ended December
31, 2022 and one customer represented 100% of revenue during the year ended December 31, 2021.
At times, the amounts on deposit at the financial institution exceed the federally insured limits. Management believes that
the financial institution which holds the Company’s cash is financially sound and, accordingly, minimal credit risk exists. As of
December 31, 2022 and 2021, the Company’s cash balances were in excess of insured limits maintained at the financial institution.
Accounts Receivable
The Company grants credit to its business customers. Collateral is generally not required for trade receivables. The
Company maintains allowances for potential credit losses when necessary. Trade accounts receivable are recorded net of allowances
for cash discounts for prompt payment, doubtful accounts, and sales returns.
The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit
losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an
allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the
realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations,
historical payment patterns of its customers and individual customer circumstances, and an analysis of days sales outstanding by
customer. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been
exhausted and the potential for recovery is considered remote. At December 31, 2022 and 2021, there were no allowances for
doubtful accounts since the balances were collected during the year.
Impairment of long-lived assets
The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that it is
more likely than not that the asset’s carrying amount may not be recoverable. The Company conducts its long-lived asset impairment
analyses in accordance with authoritative guidance which requires the Company to group assets and liabilities at the lowest level for
which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group
against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the
asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its
fair value based on discounted cash flow analysis or appraisals. During the years ended December 31, 2022 and 2021, the Company
had noted no indicators of impairment.
Property and equipment
Items capitalized as property and equipment are stated at cost. Maintenance and routine repairs are charged to operations
when incurred, while betterments and renewals are capitalized. Depreciation and amortization are computed using the straight-line
method over the estimated useful lives of the respective assets starting when the asset is placed in service.
Common stock warrants
The Company classifies as equity any warrants that (i) require physical settlement or net-share settlement or (ii) provide
the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The
Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle
the contract if an event occurs and if that event is outside the Company’s control), (ii) gives the counterparty a choice of net-cash
settlement or settlement in shares (physical settlement or net-share settlement) or (iii) that contain reset provisions that do not qualify
for the scope exception. The Company assesses classification of its common stock warrants and other freestanding derivatives at
each reporting date to determine whether a change in classification between assets and liabilities is required. The Company’s
freestanding derivatives consist of warrants to purchase common stock. The Company evaluated these warrants to assess their proper
classification and determined that the common stock warrants meet the criteria for equity classification in the balance sheet. Such
warrants are measured at fair value, which the Company determines using the Black-Scholes-Merton option-pricing model.
29
Revenue
The Company generates revenue from integration engineering services, which it delivers either pursuant to integration
license agreements or delivery of engineering services and from the grant of manufacturing licenses to customers to use its
technology in the manufacture of semiconductor wafers and/or devices for the customer’s internal use. Revenue is recognized based
on the following steps: (i) identification of the contract, or contracts, with a customer, (ii) identification of the performance
obligations in the contract, (iii) determination of the transaction price, (iv) allocation of the transaction price to the performance
obligations of the contract, and (v) recognition of revenue when, or as, the Company satisfies a performance obligation. The
Company’s integration services generally consist of depositing its proprietary technology onto the customer’s semiconductor wafers
and delivering such wafers back to the customer. Revenue from integration services is recognized as the performance obligations
are satisfied, which is upon transfer of control of the wafers to the customer (generally upon shipment). Revenue from manufacturing
licenses is recognized as the performance obligations are satisfied, which is upon delivery of the Company’s MST recipe to the
customer for the customer’s internal use.
For recognizing integration service revenue from integration license agreements, the Company assesses (i) whether the
license grant is distinct from or combined with the transfer of goods or services and (ii) whether the license is a right to access
intellectual property or a right to use the intellectual property. For licenses that are not distinct, but combined with other goods or
services, the revenue is recognized at a point in time or over time as the obligations to perform the combined services and/or deliver
the combined goods are satisfied. The Company’s integration license agreements contain a technology grant as well as a performance
obligation to deliver wafers with its technology deposited on them. The Company has determined the grant of rights in these
integration license agreements is not distinct from the integration service. Accordingly, revenue from integration license agreements
is recognized as the service is provided to the customer. For manufacturing licenses, revenue is recognized at the point in time when
the Company delivers its MST recipe because this license confers a right to use the Company’s technology and not a right to access
the technology over time. The Company’s MSTcad licenses grant customers the right to use MSTcad software to simulate the effects
of incorporating MST technology into their semiconductor manufacturing process. Such MSTcad licenses are granted on a monthly
basis and revenue is recognized over time.
Deferred revenues consist of unearned amounts that have been billed to the customer in advance of the Company’s
performance obligations. These amounts have not yet been recognized as revenue. Revenue for these items will be recognized in
accordance with the Company’s revenue policy.
Research and development expenses
In accordance with authoritative guidance, the Company charges research and development costs to operations as incurred.
Research and development expenses consist of personnel costs for the design, development, testing and enhancement of the
Company’s technology, and certain other allocated costs, such as depreciation and other facilities related expenditures.
Leases
The Company accounts for leases in accordance Financial Accounting Standards Board (“FASB”) issued Accounting
Standards Update (“ASU”) No 2016-02, Leases (Topic 842). The Company determines if a contract contains a lease in whole or in
part at the inception of the contract. Right-of-use (“ROU”) assets represent its right to use an underlying asset for the lease term
while lease liabilities represent its obligation to make lease payments arising from the lease. All leases greater than 12 months result
in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments
over the lease term. Leases are accounted for as operating leases unless it meets one of the following criteria: (a) the lease term
accounts for most of the remaining economic life of the underlying asset; (b) the present value of the lease payments is over 90% of
the fair value of the underlying asset; (c) the underlying asset would have no alternative use for the lessor at the end of the lease; or
(d) ownership of the underlying assets transfers to the Company at the end of the lease term. If the lease meets one of these criteria,
then it would be accounted for as financing lease and the ROU assets would be amortized over the life of the lease and interest
expense is recognized on the liability.
Stock-based compensation
The Company computes stock-based compensation in accordance with authoritative guidance. The Company uses the
Black-Scholes-Merton option-pricing model to determine the fair value of its stock options. The Black-Scholes-Merton option-
pricing model includes various assumptions, including the fair market value of the common stock of the Company, expected life of
stock options, the expected volatility and the expected risk-free interest rate, among others. These assumptions reflect the Company’s
best estimates, but they involve inherent uncertainties based on market conditions generally outside the control of the Company.
Forfeitures are recorded when they occur.
As a result, if other assumptions had been used, stock-based compensation cost, as determined in accordance with
authoritative guidance, could have been materially impacted. Furthermore, if the Company uses different assumptions on future
grants, stock-based compensation cost could be materially affected in future periods.
30
Income Taxes
In accordance with authoritative guidance, deferred tax assets and liabilities are recorded for temporary differences between
the financial reporting and tax bases of assets and liabilities using the current enacted tax rate expected to be in effect when the
differences are expected to reverse. A valuation allowance is recorded on deferred tax assets unless realization is considered more
likely than not.
The Company evaluates its tax positions taken or expected to be taken in the course of preparing the Company’s tax returns
to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax positions
not deemed to meet the “more-likely-than-not” threshold are not recorded as a tax benefit or expense in the current year. The
Company recognizes interest and penalties, if any, related to uncertain tax positions in interest expense. No interest and penalties
related to uncertain tax positions were accrued at either December 31, 2022 or 2021.
The Company follows authoritative guidance which requires the evaluation of existing tax positions. Management has
analyzed all open tax years, as defined by the statute of limitations, for all major jurisdictions, which includes both federal and states
where the Company has operations. Open tax years are those that are open for examination by taxing authorities.
Use of estimates
The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date
of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates are
used when accounting for revenue recognition, fair value of stock-based compensation and warrants, borrowing rates used for lease
accounting and valuation allowance against deferred tax assets. Actual results could differ from those estimates.
Subsequent events
Management has evaluated subsequent events and transactions occurring through the date these financial statements were
issued. See Note 14.
Adoption of recent accounting standards
In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and other Options (Subtopic 470-20) and
Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). The new guidance eliminates the beneficial
conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts
in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the
new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the
diluted EPS computation. This guidance is effective as of January 1, 2022 (early adoption is permitted effective January 1,
2021). The Company adopted this standard on January 1, 2022 and it did not have a material impact on its financial position, results
of operations or financial statement disclosure.
Recent accounting standards
The Company has evaluated all issued but not yet effective accounting pronouncements and determined that they are either
immaterial or not relevant to the Company.
4. REVENUE
The Company recognizes revenue in accordance with ASC 606. The amount of revenue that the Company recognizes
reflects the consideration it expects to receive in exchange for goods or services and such revenue is recognized at the time when
goods or services are transferred and/or delivered to its customers. Revenue is recognized when the Company satisfies a performance
obligation by transferring the product or service to the customer, either at a point in time or over time. The Company usually
recognizes revenue from integration service agreements and from manufacturing licenses at a point in time. Revenue from integration
license agreements and from MSTcad licenses are recognized over a period of time.
31
The following table provides information about disaggregated revenue by primary geographical markets and timing of
revenue recognition for the years ended December 31, 2022 and 2021 (in thousands):
Primary geographic markets
North America
Asia Pacific
Total
Timing of revenue recognition
Products and services transferred at a point in time
Products and services transferred over time
Total
Unbilled contracts receivable and deferred revenue:
Year Ended December 31,
2021
2022
$
$
$
$
82 $
300
382 $
375 $
7
382 $
–
400
400
400
–
400
Timing of revenue recognition may differ from the timing of invoicing customers. Accounts receivable includes amounts
billed and currently due from customers. Unbilled contracts receivable represents unbilled amounts expected to be received from
customers in future periods, where the revenue recognized to date exceeds the amount billed, and the right to receive payment is
subject to the underlying contractual terms. Unbilled contracts receivable amounts may not exceed their net realizable value and are
classified as long-term assets if the payments are expected to be received more than one year from the reporting date.
5. BASIC AND DILUTED LOSS PER SHARE`
Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares outstanding for the
period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the
weighted average number of shares of common stock outstanding and the dilutive common stock equivalent shares outstanding
during the period. The Company’s potentially dilutive common stock equivalent shares, which include incremental common shares
issuable upon (i) the exercise of outstanding stock options and warrants and (ii) vesting of restricted stock units and restricted stock
awards, are only included in the calculation of diluted net loss per share when their effect is dilutive. Since the Company has had net
losses for all periods presented, all potentially dilutive securities are anti-dilutive. Accordingly, basic and diluted net loss per share
are equal.
The following potential common stock equivalents were not included in the calculation of diluted net loss per common
share because the inclusion thereof would be anti-dilutive (in thousands):
Stock Options
Unvested restricted stock
Warrants
6. PROPERTY AND EQUIPMENT
Property and equipment consisted of the following (in thousands):
Laboratory equipment
Computer equipment
Furniture and fixtures
Leasehold improvements
Software
Office equipment
Less: Accumulated depreciation and amortization
32
Year Ended December 31,
2021
2022
3,009
340
–
3,349
2,869
386
1
3,256
December 31,
2022
2021
210 $
145
85
24
4
4
472
(314 )
158 $
200
132
85
24
4
4
449
(253 )
196
$
$
Depreciation and amortization expense relating to property and equipment was approximately $77,000 and $67,000 for the
years ended December 31, 2022 and 2021, respectively. The Company depreciates computer equipment, laboratory equipment and
office equipment on straight-line basis over three years. Furniture and fixtures are depreciated on a straight-line basis over five years.
The Company amortizes software on straight-line basis over three years. Leasehold improvements are amortized over the remaining
life of the lease.
7. LEASES
The Company leases corporate office space in Los Gatos, California. In August 2020, the Company and its landlord
amended the lease for this office. The amendment extended the expiration date of the operating lease to January 2026 and increased
the space from 3,396 square feet to 4,101 square feet. Under ASC 842, the lease amendment was treated as a separate lease for the
new space and a modification of the lease for the original space. In January 2021 the additional space became available for use, and
the Company recorded an additional ROU asset and corresponding liability of approximately $144,000. The lease liability is based
on the present value of the minimum lease payments, discounted using the Company’s estimated incremental borrowing rate of
5.25%. The lease contains escalating payments on the anniversary of the original commencement which are included in the
measurement of the initial lease liability. Additional payments based on a change in the Company’s share of the operating expenses,
including property taxes and insurance, are recorded as a period expense when incurred.
In March 2021, the Company began leasing 474 square feet of office space in Tempe, Arizona. The new lease is classified
as an operating lease with an initial term of two years and an option to extend for an additional three years through February 2026.
The renewal option was exercised in January 2023. The lease also contains a performance standard for research collaboration with
Arizona State University. The agreement requires a minimum value of collaborative research in each year of the lease. The lease is
accounted for under ASC 842 and accordingly, the research payments are included in the ROU and lease liability at the
commencement. In March 2021, the Company recorded an ROU and associated lease liability of approximately $238,000. The lease
liability is based on the present value of the minimum lease payments, discounted using the Company’s estimated incremental
borrowing rate of 5.25% over five years, as the Company expects to lease the space through the three-year extension. The lease also
contains escalating payments on the anniversary of the original commencement which are included in the measurement of the initial
lease liability.
In October 2019, the Company entered into an agreement to lease a tool for use in the development of the Company’s
technology. The lease is for five years at $150,000 per month and commenced on August 1, 2021. A prepayment of $450,000 was
made in year ended December 31, 2020 which represents the final three monthly payments under the lease and was recorded as a
long-term prepaid until the lease commencement. At commencement, the Company recorded an ROU asset of approximately $6.4
million and a corresponding lease liability of approximately $6.0 million. The lease was classified as a financing lease and
accordingly, amortization is recorded as a research and development expense in the Company’s statement of operations. Interest
expense is also recorded and included in other income or expense in the Company’s statement of operations. The lease liability is
based on the present value of the minimum lease payments, discounted using the Company’s estimated incremental borrowing rate
of 5.25% at the time of commencement. The lease payment of $150,000 per month includes approximately $30,000 in supplies and
maintenance that is recorded as an operating expense and is not included in the valuation of the lease liability. The Company elected
to exclude these costs from the asset and related lease liability valuation for this class of assets. These costs will be expensed as
operating expenses in the period incurred. This lease contains a provision for an annual adjustment of lease payments based on tool
availability and usage. The potential lease payment adjustment is determined on August 1 of each year of the lease and is calculated
based on the tool availability and usage for the preceding 12 months. Effective August 1, 2022, the lease payments for this tool were
reduced to $100,824 per month for the period August 1, 2022 through July 31, 2023. This adjustment to the variable lease payments
resulted in a reduction in ROU and corresponding lease liability.
Lease expense for operating leases consists of the lease payments recognized on a straight-line basis over the lease term.
Expenses for financing leases consists of the amortization expenses recognized on a straight-line basis over the lease term and interest
expense. The components of lease costs were as follows (in thousands):
Financing lease costs:
Amortization of ROU assets
Interest on lease liabilities
Total financing lease costs
Operating lease costs
Fixed lease costs
Short-term lease costs
Total operating lease costs
Year Ended December 31,
2021
2022
$
$
$
$
1,229 $
255
1,484 $
248 $
35
283 $
532
128
660
238
44
282
33
Future minimum payments under non-cancellable leases as of December 31, 2022 were as follows (in thousands):
For the Year Ended December 31,
2023
2024
2025
2026
Total future minimum lease payments
Less imputed interest
Total lease liability
Financing leases Operating leases
253
$
278
284
21
836
(70 )
766
1,161 $
1,436
1,436
478
4,511
(399 )
4,112 $
$
The below table provides supplemental information and non-cash activity related to the Company’s operating and financing
leases are as follows (in thousands):
Operating cash flow information:
Cash paid for amounts included in the measurement of operating lease liabilities
Cash paid for amounts included in the measurement of financing lease liabilities
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations
Right-of-use assets obtained in exchange for financing lease obligations
Remeasurement of right-of use asset and liability in financing lease obligations
Year Ended December 31,
2021
2022
$
$
$
$
$
265 $
1,239 $
– $
– $
(458 ) $
143
598
382
6,383
–
The weighted average remaining discount rate is 5.25% for the Company’s operating and financing leases. The weighted
average remaining lease term is 3.6 years for financing lease and 3.1 years for operating leases.
In October 2016, the Company entered into lease agreement for approximately 200 square feet of office space in Cambridge,
Massachusetts. The lease, with current monthly payments of $2,942 per month, commenced on October 24, 2016. Since the lease is
month to month and can be cancelled with a 30-day notice, the future lease payments are not included in the Company’s lease
accounting under ASC Topic 842.
In December 2022, the Company entered into a lease agreement for a tool in Tempe, Arizona. The term of this lease is for
six months beginning on January 1, 2023 with an option to extend the lease for an additional six months. The initial lease terms are
for $96,000 per month. If the option to extend the lease is exercised prior to March 31, 2023, the remaining lease payments will be
reduced to an average of $87,000 over the twelve months. Since the lease and extension are not for more than one year, the future
lease payments are not included in the Company’s lease accounting under ASC Topic 842.
8. COMMITMENTS AND CONTINGENCIES
Legal
The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its
business. Such matters are subject to many uncertainties and outcomes and are not predictable with assurance. While management
believes that such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or
could become involved in litigation may have a material adverse effect on its business and financial condition. The Company is not
party to any material litigation as of December 31, 2022 or through the date these financial statements have been issued.
9.
STOCKHOLDERS’ EQUITY
The Company is authorized to issue to up 2,500,000 shares of preferred stock, $.001 par value. As of December 31, 2022,
and 2021, no shares have been designated and no shares are issued and outstanding. Preferred stock may rank prior to common stock
with respect to dividends rights, liquidation preferences, or both, and may have full or limited voting rights.
On September 2, 2020, Atomera entered into an Equity Distribution Agreement with Craig-Hallum Capital Group LLC, as
agent, under which the Company offered and sold, from time to time at its sole discretion, shares of its common stock having
aggregate offering proceeds of up to $25.0 million in an “at-the-market” or ATM offering, to or through the agent. On January 5,
2021 we announced the completion of this offering after 2,221,575 shares were sold for an average price per share of $11.25, resulting
in approximately $24.2 million of net proceeds to us after deducting commissions and other offering expenses.
On May 31, 2022, Atomera entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc and Craig-Hallum
Capital Group LLC, as agents, under which we may offer and sell, from time to time at our sole discretion, shares of our common
34
stock having aggregate offering proceeds of up to $50.0 million in an “at-the-market” or ATM offering, to or through the agents.
During the year ended December 31, 2022, approximately 527,000 shares were sold at an average price per share of approximately
$11.68, resulting in approximately $5.8 million of net proceeds to us after deducting commissions and other offering expenses.
As of December 31, 2022, the Company has reserved approximately 3.0 million shares of common stock for issuance
pursuant to outstanding stock options.
10. WARRANTS
The Company estimated the fair value of warrants using the Black-Scholes option pricing model. There were no warrants
issued in the year ending December 31, 2022 or 2021. A summary of warrant activity for the year ended December 31, 2021 is as
follows (shares in thousands except per share and contractual term):
Outstanding at January 1, 2022
Expired
Outstanding and exercisable at December 31, 2022
11. STOCK-BASED COMPENSATION
Number of
Shares
Weighted-
Average
Exercise
Prices
1 $
(1 ) $
– $
33.75
33.75
–
The Company’s 2007 Equity Incentive Plan (the “2007 Plan) expired in March 2017, however all options and warrants
outstanding at the time of the expiration remained outstanding and exercisable by their term. At the time of the expiration of the
2007 plan, options to purchase 2,106,637 shares of common stock were outstanding.
In May 2017, the Company’s shareholders approved its 2017 Stock Incentive Plan (“2017 Plan”). The 2017 Plan provides
for the grant of non-qualified stock options and incentive stock options to purchase shares of the Company’s common stock and for
the grant of restricted and unrestricted share grants. The Company reserved a total of 3,750,000 shares of common stock for issuance
under the 2017 Plan. All employees, officers, directors, consultants, advisors and other persons who provide services to the Company
or any subsidiaries of the Company are eligible to receive incentive awards under the 2017 Plan. As of December 31, 2022, awards
of 3,072,791 shares of common stock had been granted under the 2017 Plan, net of forfeited restricted stock and option awards and
a total of 677,209 shares of common stock are reserved for issuance.
The following table summarizes the stock-based compensation expense recorded in the Company’s results of operations
during the years ended December 31, 2022 and 2021 for stock options and restricted stock (in thousands):
Research and development
General and administrative
Selling and Marketing
Year Ended December 31,
2021
2022
$
$
1,153 $
1,965
249
3,367 $
907
1,893
173
2,973
As of December 31, 2022, there was approximately $6.3 million of total unrecognized compensation expense related to
non-vested share-based compensation arrangements that are expected to vest. This cost is expected to be recognized over a weighted-
average period of 2.0 years.
The Company records compensation expense for employee awards with graded vesting using the straight-line method. The
Company records compensation expense for nonemployee awards with graded vesting using the accelerated expense attribution
method. The Company recognizes compensation expense over the requisite service period applicable to each individual award, which
generally equals the vesting term. The Company estimates the fair value of each option award using the Black-Scholes-Merton
option pricing model. Forfeitures are recognized when realized.
35
The fair value of employee stock options issued was estimated using the following weighted-average assumptions:
Weighted average exercise price:
Weighted average grant date fair value per share:
Assumptions:
Expected volatility
Weighted average expected term (in years)
Risk-free interest rate
Expected dividend yield
$
$
Year Ended December 31,
2021
2022
14.21 $
10.37 $
83.18%
6.51
1.96%
0.0%
22.05
15.49
81.11%
6.34
1.05%
0.0%
The risk-free interest rate was obtained from U.S. Treasury rates for the applicable periods. The Company’s expected
volatility was based upon the historical volatility of the Company. The expected life of the Company’s options was determined using
the simplified method as a result of limited historical data regarding the Company’s activity. The dividend yield considers that the
Company has not historically paid dividends and does not expect to pay dividends in the foreseeable future.
The following table summarizes stock option activity during the year ended December 31, 2022 (in thousands except
exercise prices and contractual terms):
Outstanding at January 1, 2022
Granted
Exercised
Forfeited
Expired
Outstanding at December 31, 2022
Exercisable at December 31, 2022
Number of
Shares
Weighted-
Average
Exercise
Prices
2,869 $
196 $
(45 ) $
(3 ) $
(8 ) $
3,009 $
2,585 $
6.64
14.21
5.38
28.66
33.09
7.07
6.45
Weighted-
Average
Remaining
Contractual
Term
(In Years)
Intrinsic
Value
5.07 $
4.57 $
2,249
1,837
During the year ended December 31, 2022, the Company granted options under its 2017 Plan purchase approximately
196,000 shares of its common stock to its employees. The fair value of these options was approximately $2.0 million.
The Company issues restricted stock to employees, directors and consultants and estimates the fair value based on the
closing price on the day of grant. The following table summarizes all restricted stock activity during the year ended December 31,
2022 (in thousands except per share data):
Outstanding at January 1, 2022
Granted
Vested
Outstanding non-vested shares at December 31, 2022
12. 401(k) PLAN
Number of
Shares
Weighted-
Average Grant
Date Fair Value
6.75
14.41
7.22
10.78
386 $
194 $
(240 ) $
340 $
During 2002, the Company established a plan under Section 401(k) of the Internal Revenue Code (the 401(k) Plan). The
401(k) Plan covers substantially all of its employees who have attained 18 years of age. Employees may elect to contribute part of
their annual compensation to the 401(k) Plan, up to the maximum deferral allowance for individuals by the Internal Revenue Service
under Code Section 401(k), and the Company may make a matching contribution. During the year ended December 31, 2022, there
were matching contributions of approximately $78,000. During the year ended December 31, 2021, no matching contributions were
made by the Company.
36
13. INCOME TAXES
The loss before provision for income taxes consisted of the following (in thousands):
Domestic
International
Total
Year Ended December 31,
2021
2022
$
$
(17,441 ) $
–
(17,441 ) $
(15,648 )
–
(15,648 )
The Company had $0 and $66,000 of current income tax expense for the years ended December 31, 2022 and 2021,
respectively. The income tax expense for 2022 related to taxes due to a foreign country arising from withholding taxes imposed on
payments received for revenue. The Company accounts for income taxes in accordance with ASC 740, which requires that the tax
benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management
assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company's ability to
generate sufficient taxable income within the carryforward period. Because of the Company's recent history of operating losses,
management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not
likely to be realized and, accordingly, has provided a full valuation allowance. The valuation allowance increased by approximately
$4.5 million during the year ended December 31, 2022 and decreased by approximately $1.8 million during the year ended December
31, 2021.
The Company’s deferred tax assets are as follows (in thousands):
Deferred tax assets:
Net operating loss carryforwards
Tax credit
Fixed assets and intangibles
Stock compensation
Accruals and other
Lease liability
Capitalized research and development
Total deferred tax assets
Deferred tax liabilities:
Right of use asset
Total deferred tax assets
Valuation allowance
Net deferred tax asset
Year Ended December 31,
2021
2022
$
$
25,309 $
2,197
798
1,052
212
1,079
1,797
32,444
(1,076 )
(1,076 )
(31,368 )
– $
23,097
1,883
978
799
132
1,430
–
28,319
(1,477 )
(1,477 )
(26,842 )
–
Net operating losses and tax credit carryforwards as of December 31, 2022, are as follows (in thousands):
Net operating losses, federal
Net operating losses, federal
Net operating losses, state
Tax credits, federal
Tax credits, state
Tax credits, state
Amount
Expiration in years
$
$
$
$
$
$
75,247
34,791
38,973
1,835
756
894
No expiration
2027-2037
2030-2042
2027-2042
No expiration
2022-2037
37
The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as
follows:
Statutory rate
State rate
Change in valuation allowance
Change in tax credits
Foreign withholding tax
Section 382 limitation
Section 162(m) limitation
Stock based compensation excess windfall
Total
Year ending December 31,
2021
2022
21.00%
3.51%
(25.95 )%
0.70%
–%
–%
(0.47 )%
1.20%
–%
21.00%
2.77%
11.41%
4.54%
(0.33 )%
(51.59 )%
(9.12 )%
20.89%
(0.42 )%
Utilization of U.S. net operating losses and tax credit carryforwards may be limited by “ownership change” rules, as defined
in Section 382 and Section 383 of the Internal Revenue Code. Similar rules may apply under state tax laws. Under those sections of
the Code, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss
carryforwards and other pre-change attributes, such as research tax credits, to offset its post-change income or tax may be limited.
In general, an “ownership change” will occur if there is a cumulative change in ownership by “5% stockholders” that exceeds 50
percentage points over a rolling three-year period.
During the year ended 2021, the Company performed an analysis to assess whether an “ownership change,” as defined by
Section 382 of the Code, has occurred from its inception through December 31, 2021. Based on this analysis, the Company has
experienced “ownership changes,” limiting the utilization of the net operating loss carryforwards or research and development tax
credit carryforwards under Section 382 of the Code. The limitation is calculated by first multiplying the value of the Company’s
stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then applying additional adjustments, as
required. As a result of the analysis, the Company has determined that approximately $31 million of federal net operating loss and
$0.7 million of federal R&D credit carryforwards are limited and will expire unutilized. Additionally, approximately $2.6 million of
state net operating loss and $0.5 million of state tax credits are also limited and will expire unutilized. The Company’s tax disclosures
as of December 31, 2022 and 2021 reflect the impairment of the above-mentioned tax attributes.
The Company establishes reserves for uncertain tax positions based on the largest amount that is more-likely-than-not to
be sustained. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. It is the
Company’s policy to recognize interest and penalties related to income tax matters in income tax expense. As of December 31, 2022
and 2021, respectively, the Company has no accrued interest or penalties related to uncertain tax positions.
The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. In the normal course
of business, the Company is subject to examination by their respective taxing authorities. The Company is not currently under audit
by the Internal Revenue Service or other similar state or local authority. The statute of limitations remains effectively open for all
tax years since inception (2007). Tax years outside the normal statute of limitations remain open to examination by tax authorities
due to tax attributes generated in earlier years which have been carried forward and may be examined and adjusted in subsequent
years when utilized.
The following table summarizes the activity related to the Company’s gross unrecognized tax benefits for the years ended
December 31, 2022 and 2021 (in thousands):
January 1 – unrecognized tax benefits
Increases (decreases) – prior year tax positions
Increases – current year tax positions
December 31 - unrecognized tax benefits
2022
2021
$
$
896 $
(1 )
151
1,046 $
1,070
(480 )
306
896
38
The following table summarizes the activity in the Company’s Valuation Allowance and Qualifying Accounts for the years
ended December 31, 2022 and 2021 (in thousands):
Deferred tax assets valuation allowance
Year ended December 31, 2022
Year ended December 31, 2021
14. SUBSEQUENT EVENTS
Balance at
Beginning
of Year
Additions
Deductions
Balance
at End of
Year
$
$
26,842 $
28,627 $
4,636 $
6,125 $
110 $
7,910 $
31,368
26,842
Management has evaluated subsequent events and transactions through the date these financial statements were issued.
39
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
Item 9A. Controls and Procedures
(a) Evaluation of Disclosure Controls and Procedures.
Our management, with the participation of our chief executive officer and chief financial officer evaluated the effectiveness
of our disclosure controls and procedures pursuant to Rule 13a-15(e) under the Exchange Act. Based upon that evaluation, our
management, including our chief executive officer and chief financial officer, concluded that our disclosure controls and procedures
were effective as of December 31, 2022 in ensuring all material information required to be disclosed by us is recorded, processed,
summarized and reported, within the time periods specified in the Commission's rules and forms, and that such information is
accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate,
to allow timely decisions regarding required disclosure.
(b) Changes in internal control over financial reporting.
There were no changes to our internal control over financial reporting, as defined in Rules 13a-15(f) under the Exchange
Act that occurred during the quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.
(c) Management’s report on internal controls over financial reporting.
Our management is responsible for establishing and maintaining adequate internal controls over financial reporting, as
defined under Rule 13a-15(f) under the Exchange Act. Our management has assessed the effectiveness of our internal controls over
financial reporting as of December 31, 2022 based on the framework established in Internal Control - Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) (“COSO”). Our internal control
system was designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair
presentation of published financial statements. Our management assessed the effectiveness of our internal control over financial
reporting as of December 31, 2022, and based on that evaluation, management concluded that our internal control over financial
reporting was effective as of December 31, 2022.
This report does not include an attestation report of our registered public accounting firm regarding internal control over
financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to the rules
of the Securities and Exchange Commission that permit us to provide only management’s report in this Annual Report.
Item 9B. Other Information
Not applicable.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not applicable.
40
PART III
The information required by Part III is omitted from this report because we will file a definitive proxy statement within 120
days after the end of our 2022 fiscal year pursuant to Regulation 14A for our 2023 Annual Meeting of Stockholders, or the 2023
Proxy Statement, and the information to be included in the 2022 Proxy Statement is incorporated herein by reference.
Item 10.
Directors, Executive Officers and Corporate Governance
The information required under this item will be contained in the 2023 Proxy Statement and is hereby incorporated by
reference.
Item 11.
Executive Compensation
The information required under this item will be contained in the 2023 Proxy Statement and is hereby incorporated by
reference.
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters
The information required under this item will be contained in the 2023 Proxy Statement and is hereby incorporated by
reference.
Item 13.
Certain Relationships and Related Transactions, and Director Independence
The information required under this item will be contained in the 2023 Proxy Statement and is hereby incorporated by
reference.
Item 14.
Principal Accountant Fees and Services
The information required under this item will be contained in the 2023 Proxy Statement and is hereby incorporated by
reference.
41
Item 15.
Exhibits and Financial Statement Schedules
(a) Financial Statements
PART IV
(1) Financial statements for our company are listed in the index under Item 8 of this document
(2) All financial statement schedules are omitted because they are not applicable, not material or the required information
is shown in the financial statements or notes thereto.
Exhibit
No.
Description
Method of Filing
3.1
Amended and Restated Certificate of Incorporation of the
Incorporated by reference from the Registrant’s
Registrant
3.2
Amended and Restated Bylaws of the Registrant
Registration Statement on Form S-1 filed on June 30,
2016.
Incorporated by reference from the Registrant’s
Registration Form 8-K filed on October 27, 2021.
3.3
Certificate of Amendment to Amended and Restated Certificate
Incorporated by reference from the Registrant’s
of Incorporation of the Registrant
Registration Statement on Form S-1 filed on June 30,
2016.
3.4
Certificate of Amendment to Amended and Restated Certificate
Incorporated by reference from the Registrant’s
of Incorporation of the Registrant
4.1
Description of Capital Stock
Registration Statement on Form S-1 filed on June 30,
2016.
Incorporated by reference from the Registrant’s
Annual Report on Form 10-K filed on February 19,
2021
10.1
Assignment of Patent Rights dated April 3, 2009 between Dr.
Incorporated by reference from the Registrant’s
Robert Mears and the Registrant
10.2+
2007 Stock Incentive Plan
Registration Statement on Form S-1 filed on June 30,
2016.
Incorporated by reference from the Registrant’s
Registration Statement on Form S-1 filed on June 30,
2016.
10.3
Exclusive License and Collaboration Agreement dated March 3,
Incorporated by reference from the Registrant’s
2010 between K2 Energy Limited and the Registrant
Registration Statement on Form S-1 filed on June 30,
2016.
10.4
Letter Agreement dated June 6, 2014 between K2 Energy
Incorporated by reference from the Registrant’s
Limited and the Registrant
Registration Statement on Form S-1 filed on June 30,
2016.
10.5
Lease Agreement dated January 19, 2016 between 750
Incorporated by reference from the Registrant’s
University, LLC and the Registrant
10.6+
Form of Restricted Stock Agreement
10.7+
Atomera Incorporated 2017 Stock Incentive Plan
Registration Statement on Form S-1 filed on June 30,
2016.
Incorporated by reference from the Registrant’s
Amendment No. 1 to Registration Statement on Form
S-1 filed on July 29, 2016
Incorporated by reference from the Registrant’s
Definitive Proxy Statement filed on April 10, 2017.
10.8
First Amendment to Lease Agreement dated January 19, 2016
Incorporated by reference from the Registrant’s Form
between 750 University, LLC and the Registrant
10-K filed on March 6, 2018.
42
10.9+
Employment Agreement dated January 26, 2021 between Scott
Bibaud and the Registrant
Incorporated by reference from the Registrant’s
Annual Report on Form 10-K filed on February 19,
2021
10.10+
Employment Agreement dated January 26, 2021 between Frank
Incorporated by reference from the Registrant’s
Laurencio and the Registrant
Annual Report on Form 10-K filed on February 19,
2021
10.11+
Employment Agreement dated January 26, 2021 between Dr.
Incorporated by reference from the Registrant’s
Robert Mears and the Registrant
Annual Report on Form 10-K filed on February 19,
2021
10.12+
Employment Agreement dated January 26, 2021 between Jeffrey
Lewis and the Registrant
Incorporated by reference from the Registrant’s
Registration Form 8-K filed on June 3, 2021
10.13
Second Amendment to Lease Agreement dated January 19, 2016
Incorporated by reference from the Registrant’s
between 750 University, LLC and the Registrant
Annual Report on Form 10-K filed on February 19,
2021
10.14
Equity Distribution Agreement dated May 31, 2022 between the
Incorporated by reference from the Company’s
Company and Oppenheimer & Co. Inc. and Craig-Hallum
Capital Group LLC
Current Report on Form 8-K filed on May 31, 2022
21.1
List of Subsidiaries
Incorporated by reference from the Registrant’s
Registration Statement on Form S-1 filed on June 30,
2016.
23.1
Consent of Marcum LLP, Independent Registered Public
Filed electronically herewith
Accounting Firm
31.1
Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act
Filed electronically herewith
of 2002.
31.2
Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act
Filed electronically herewith
of 2002.
32.1
Certification of Principal Executive Officer and Principal
Filed electronically herewith
Financial Officer pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002 (18 U.S.C. Section 1350).
101.INS XBRL Instance Document
Filed electronically herewith
101.SCH XBRL Taxonomy Extension Schema Document
Filed electronically herewith
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
Filed electronically herewith
101.LAB XBRL Taxonomy Extension Label Linkbase Document
Filed electronically herewith
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document Filed electronically herewith
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
Filed electronically herewith
+ Indicated management compensatory plan, contract or arrangement.
Item 16.
Form 10-K Summary
None provided.
43
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Date: February 15, 2023
Date: February 15, 2023
ATOMERA INCORPORATED.
By:
/s/ Scott A. Bibaud
Scott A. Bibaud
Chief Executive Officer,
(Principal Executive Officer)
and Director
By: /s/ Francis B. Laurencio
Francis B. Laurencio
Chief Financial Officer
(Principal Financial and
Accounting Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on
behalf of the registrant and in the capacities and on the dates indicated.
Signature
/s/Scott A. Bibaud
Scott A. Bibaud
/s/John D. Gerber
John Gerber
/s/ Steven K. Shevick
Steven K. Shevick
/s/ Duy-Loan Le
Duy-Loan Le
/s/Suja Ramnath
Suja Ramnath
Title
Date
Chief Executive Officer and Director
(Principal Executive Officer)
February 15, 2023
Director and Chairman
February 15, 2023
Director
Director
Director
February 15, 2023
February 15, 2023
February 15, 2023
44